SECURITIES AND EXCHANGE COMMISSION
___________________
FORM 10-K
(Mark one)
[X] |
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) |
OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the Fiscal Year Ended March 31, 2001
[ ] |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) |
OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period From _____ to _____
Commission File No. 1-5438
FOREST LABORATORIES, INC.
Delaware |
|
11-1798614 |
909 Third Avenue |
|
10022 |
(212) 421-7850
(Registrant's telephone number, including area code)
Securities registered pursuant to Section 12(b) of the act:
|
|
Name of each exchange |
Common Stock, $.10 par value |
|
New York Stock Exchange |
|
|
Securities registered pursuant to Section 12(g) of the act:
None
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes X No .
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein and will not be contained, to the best of the registrant's knowledge, in the Proxy Statement incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. .
The aggregate market value of the voting stock held by non-affiliates of the registrant as of June 22, 2001 is $12,373,346,400.
Number of shares outstanding of the registrant's Common Stock as of June 22, 2001: 176,996,091.
The following documents are incorporated by reference herein:
Portions of the definitive proxy statement to be filed pursuant to Regulation 14A promulgated under the Securities Exchange Act of 1934 in connection with the 2001 Annual Meeting of Stockholders of registrant.
Portions of the registrant's Annual Report to Stockholders for the fiscal year ended March 31, 2001.
_________________
PART I
ITEM 1. BUSINESS
General
Forest Laboratories, Inc. and its subsidiaries (collectively, "Forest" or the "Company") develop, manufacture and sell both branded and generic forms of ethical drug products which require a physician's prescription, as well as non-prescription pharmaceutical products sold over-the-counter. Forest's most important United States products consist of branded ethical drug specialties marketed directly, or "detailed," to physicians by the Company's Forest Pharmaceuticals, Forest Therapeutics and Forest Specialty Sales salesforces. The Company emphasizes detailing to physicians of those branded ethical drugs it believes have the most potential for growth, and the development and introduction of new products, including products developed in collaboration with licensing partners.
Forest's products include those developed by Forest and those acquired from other pharmaceutical companies and integrated into Forest's marketing and distribution systems. See "Recent Developments."
Forest is a Delaware corporation organized in 1956, and its principal executive offices are located at 909 Third Avenue, New York, New York 10022 (telephone number (212-421-7850).
Recent Developments
Neramexane: In March 2001 Forest entered into an agreement with Merz + Co., a privately-held pharmaceutical firm based in Frankfurt, Germany to jointly develop neramexane, a newly patented NMDA antagonist which is being developed for several central nervous system disorders.
Escitalopram: In March 2001, Forest submitted a New Drug Application ("NDA") with the United States Food and Drug Administration ("FDA") seeking approval to market escitalopram, a single isomer version of Forest's Celexa™ (citalopram HBr) for the treatment of depression. Citalopram is a racemic mixture with two mirror image molecules, the S- and R-isomers. The S-isomer of citalopram is the active isomer in terms of its contribution to citalopram's antidepressant effects, while the R-isomer does not contribute to the antidepressant activity. With escitalopram, the R-isomer has been removed, leaving only the active S-isomer. Clinical trials demonstrate that escitalopram is a more potent and selective serotonin reuptake inhibitor than its parent compound and confirm the antidepressant activity of escitalopram in all clinical measures of depression. Escitalopram was developed by H. Lundbeck A/S, a Danish pharmaceutical firm which licenses this compound, as well as Celexa, to Forest.
Celexa: Sales of Celexa, Forest's selective serotonin reuptake inhibitor ("SSRI") for the treatment of depression were $714,359,000 for the fiscal year ended March 31, 2001. According to data published by IMS, an independent prescription audit firm, as of June 8, 2001 Celexa has achieved a 14.6% share of total prescriptions for antidepressants in the SSRI category. Citalopram is currently marketed in most European countries and is the leading antidepressant in several European markets. Forest licenses the United States rights to Celexa from H. Lundbeck A/S.
Memantine: In June 2000, Forest entered into a license agreement with Merz + Co. for the exclusive rights to develop and market memantine in the United States. Memantine is the leading prescription product sold for dementia in Germany. Several large scale studies in Alzheimer's Disease and dementia have been completed, including one in the United States, which demonstrate that the compound is well tolerated and capable of treating the symptoms of Alzheimer's Disease. In addition, a clinical study has demonstrated that memantine is helpful in relieving nighttime neuropathic pain in diabetic patients. Forest intends to prepare an NDA submission for the treatment of moderate to severe Alzheimer's Disease based upon the studies performed to date for submission around the end of 2001. The FDA has indicated that one of the two pivotal studies does not meet its current requirements and that it is likely to submit the application to its advisory committee. The Company is also performing three additional clinical studies in Alzheimer's Disease to further supplement the completed trials and it is anticipated that the results of the first of these studies should be available by the end of 2002. Forest will also begin additional studies in neuropathic pain.
Lercanidipine: In November 2000, Forest entered into a license agreement with Recordati S.p.A., a privately-held pharmaceutical company based in Milan, Italy, for the exclusive rights to develop and market lercanidipine in the United States for the treatment of hypertension. Lercanidipine, currently marketed in twenty-five countries, belongs to the dihydropyridine calcium channel blocker class of antihypertensives, one of the most widely used classes of antihypertensives. Lercanidipine has been widely studied in clinical trials and was found to have an excellent safety profile and comparable blood pressure lowering effects to other drugs in this class. Forest plans to file an NDA for lercanidipine based upon the current European study dossier in the second half of 2001.
Dexloxiglumide: In August 2000, Forest concluded a license arrangement with Rotta Research Laboratorium S.p.A. of Monza, Italy, for the exclusive rights to develop and market in the United States dexloxiglumide for the treatment of patients with constipation predominant irritable bowel syndrome. Irritable bowel syndrome is a chronic intestinal disorder characterized by recurrent abdominal pain and bloating, accompanied by constipation or diarrhea. Current treatments include diet, laxatives and antispasmodic drugs. Dexloxiglumide is a cholecystokinin ("CCK") receptor antagonist. CCK antagonists increase gastric emptying and intestinal motility and may reduce moderate intestinal sensitivity to distension. A successful Phase II study has already been completed. Forest intends to commence Phase III studies for dexloxiglumide in the United States in the second half of 2001.
ML3000: In March 2000 Forest entered into a Joint Development, License and Supply Agreement with the German pharmaceutical company Merckle GmbH for the development and marketing in the United States of ML3000, a novel compound being investigated for its role in the management of osteoarthritis, a degenerative joint disease that affects an estimated 21 million Americans.
ML3000 is a new entity in a novel class of dual-acting, anti-inflammatory drugs called COX/LO inhibitors. These drugs simultaneously inhibit the enzymes cyclooxygenase ("COX") and 5-lipoxygenase ("LO"), both of which are involved in the inflammatory process. Leukotrienes, inflammatory products generated by LO, are believed to contribute to the gastrointestinal irritation caused by traditional non-steroidal anti-inflammatory drugs and may also contribute to the inflammation related symptoms seen in osteoarthritis. In several Phase II studies, ML3000 was well tolerated and reduced the symptoms of pain and stiffness in patients with osteoarthritis of the knee. In addition, fewer gastrointestinal side effects were observed in normal volunteers tested with ML3000 by comparison to a standard regimen of naprosyn after 30 days of treatment. Phase III studies are ongoing in Europe and will be initiated in the United States in 2001.
Flunisolide HFA: On December 3, 1999, Forest and the 3M Pharmaceuticals Division of the Minnesota Mining and Manufacturing Company ("3M") entered into a Supply and Distribution Agreement for the long-term supply and manufacture by 3M on an exclusive basis of a hydrofluroalkane ("HFA") formulation of flunisolide, the active ingredient in Aerobid, Forest's metered dose inhaled steroid for the treatment of asthma. The HFA formulation does not contain chlorofluorocarbons, which are being phased out of commercial use due to environmental concerns. In addition, the HFA formulation of flunisolide incorporates a built-in spacer device which Forest believes will enhance use of the product. Forest filed an NDA with the FDA for the HFA formulation of Aerobid® on April 27, 2000, and received an approvable letter in May 2001. The Company expects to begin marketing HFA flunisolide in late calendar 2001 or early 2002 after final approval.
Tiazac®: Tiazac, launched in 1996, is Forest's once-daily formulation of diltiazem, used in the treatment of hypertension and angina. While no generic equivalent to Tiazac has been approved by the FDA, a generic manufacturer has filed an Abbreviated New Drug Application ("ANDA") with the FDA for a generic formulation. Litigation is pending between Biovail Corporation, Forest's licensor of Tiazac, and the generic manufacturer with respect to this ANDA and formulation and it is uncertain at this time whether or when approval of such generic product might occur.
ALX-0646: Pursuant to a license agreement with NPS Allelix Corp. of Mississauga, Ontario, Canada, Forest is investigating a novel compound developed by Allelix for the treatment of migraine headaches. Preliminary research suggests this compound, which acts selectively on certain serotonin receptor subtypes, may be capable of treating migraine headaches, while producing less vasoconstriction, which is thought to cause the cardiovascular adverse events sometimes reported for this class of compounds. Additional pre-clinical pharmacology and toxicology studies are ongoing and Forest plans to initiate a Phase I study in the United States in 2001.
Siramesine: Forest continues development of siramesine (Lu28-179), a compound for the treatment of anxiety which was included in a 1998 joint venture collaboration with H. Lundbeck A/S. The compound is currently being tested in a Phase I study.
Research and Development Facility: In March 2000, Forest acquired a 100,000 square foot facility in Commack, New York. Forest is developing a research and development facility at this location, which is expected to become operational in fiscal 2003.
Stock Split: On January 11, 2001, the Company completed a two-for-one stock split, effected as a stock dividend of one share for each share issued and outstanding as of December 26, 2000. All share information set forth or incorporated by reference in this Report gives effect to the stock split.
Forward Looking Statements: Except for the historical information contained herein, this report contains forward looking statements that involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing and the uncertainty and timing of the development and launch of new pharmaceutical products.
Principal Products
The Company actively promotes in the United States those of its branded products which the Company's management believes have the most potential for growth and which enable its salesforces to concentrate on groups of physicians who are high prescribers of its products. Such products include Celexa, Forest's SSRI for the treatment of depression; the respiratory products Aerobid and Aerochamber®; Tiazac, Forest's once-daily diltiazem for the treatment of hypertension and angina; and Infasurf®, a lung surfactant for the treatment and prevention of respiratory distress syndrome in premature infants.
Sales of Celexa, launched in September 1998, accounted for 60.8% of Forest's sales for the fiscal year ended March 31, 2001 and 49.0% and 16.8%, respectively, of Forest's sales for the fiscal years ended March 31, 2000 and 1999.
Aerobid is a metered dose inhaled steroid used in the treatment of asthma. Sales of Aerobid accounted for 5.2% of Forest's sales for the fiscal year ended March 31, 2001, as compared to 7.3% and 16.9% for the fiscal years ended March 31, 2000 and 1999, respectively. Aerochamber is a spacer device used to improve the delivery of products administered by aerosol delivery, including Aerobid.
Sales of Tiazac, launched in 1996, accounted for 15.1%, 18.1% and 23.7% of sales for the fiscal years ended March 31, 2001, 2000 and 1999, respectively .
Forest's generic line, marketed by the Company's Inwood Laboratories, Inc. subsidiary, includes generic equivalents to certain of the Company's branded products, as well as difficult to formulate controlled release products.
The Company's United Kingdom and Ireland subsidiaries sell both ethical products requiring a doctor's prescription and over-the-counter preparations. Their most important products include Sudocrem®, a topical preparation for the treatment of diaper rash; Colomycin®, an antibiotic used in the treatment of Cystic Fibrosis; Suscard® and Sustac®, sustained action nitroglyerin tablets in both buccal and oral form used in the treatment of angina pectoris, an ailment characterized by insufficient oxygenation of the heart muscle and Exorex®, used in the treatment of eczema and psoriasis.
Marketing
In the United States, Forest directly markets its products through its domestic salesforces, Forest Pharmaceuticals, Forest Therapeutics and Forest Specialty Sales, currently numbering 1,450 persons, which detail products directly to physicians, pharmacies and managed care organizations. The Company also employs a contract salesforce of 226 representatives to promote its products. In the United Kingdom, the Company's Pharmax subsidiary's salesforce, currently 28 persons, markets its products directly. Forest's products are sold elsewhere through independent distributors.
Competition
The pharmaceutical industry is highly competitive as to the sale of products, research for new or improved products and the development and application of competitive controlled release and other drug formulation and delivery technologies. There are numerous companies in the United States and abroad engaged in the manufacture and sale of both proprietary and generic drugs of the kind sold by Forest and drugs utilizing controlled release technologies. Many of these companies have substantially greater financial resources than Forest. The Company also faces competition for the acquisition or licensing of new product opportunities from other companies. In addition, the marketing of pharmaceutical products is increasingly affected by the growing role of managed care organizations, including pharmaceutical benefit management companies, in the provision of health services. Such organizations negotiate with pharmaceutical manufacturers for highly competitive prices for pharmaceutical products in equivalent therapeutic categories, including certain of the Company's principal promoted products. Failure to be included or to have a preferred position in a managed care organization's drug formulary could result in decreased prescriptions of a manufacturer's products.
Government Regulation
The pharmaceutical industry is subject to comprehensive government regulation which substantially increases the difficulty and cost incurred in obtaining the approval to market newly proposed drug products and maintaining the approval to market existing drugs. In the United States, products developed, manufactured or sold by Forest are subject to regulation by the FDA, principally under the Federal Food, Drug and Cosmetic Act, as well as by other federal and state agencies. The FDA regulates all aspects of the testing, manufacture, safety, labeling, storage, record keeping, advertising and promotion of new and old drugs, including the monitoring of compliance with good manufacturing practice regulations. Non-compliance with applicable requirements can result in fines and other sanctions, including the initiation of product seizures, injunction actions and criminal prosecutions based on practices that violate statutory requirements. In addition, administrative remedies can involve voluntary recall of products as well as the withdrawal of approval of products in accordance with due process procedures. Similar regulations exist in most foreign countries in which Forest's products are manufactured or sold. In many foreign countries, such as the United Kingdom, reimbursement under national health insurance programs frequently require that manufacturers and sellers of pharmaceutical products obtain governmental approval of initial prices and increases if the ultimate consumer is to be eligible for reimbursement for the cost of such products.
During the past several years the FDA, in accordance with its standard practice, has conducted a number of inspections of the Company's manufacturing facilities. Following these inspections the FDA called the Company's attention to certain "Good Manufacturing Practices" compliance and record keeping deficiencies. Forest has responded to the FDA's comments and has modified procedures to comply with the requests made by the FDA.
In March 1997, the FDA announced a proposed rule which could result in the withdrawal of approval to market metered dose inhaler formulations of corticosteroids (such as the Company's Aerobid product) containing chlorofluorocarbons ("CFC's") once three distinct non-CFC products are available in that therapeutic category. The Company has developed a non-CFC formulation of flunisolide (the active ingredient in Aerobid) and has filed an NDA with the FDA covering this formulation. (See "Recent Developments.") Forest received an "approvable" letter from the FDA in May 2001 and expects to receive NDA approval in time to meet the proposed rule.
The cost of human health care products continues to be a subject of investigation and action by governmental agencies, legislative bodies and private organizations in the United States and other countries. In the United States, most states have enacted generic substitution legislation requiring or permitting a dispensing pharmacist to substitute a different manufacturer's version of a drug for the one prescribed. Federal and state governments continue to press efforts to reduce costs of Medicare and Medicaid programs, including restrictions on amounts agencies will reimburse for the use of products. Under the Omnibus Budget Reconciliation Act of 1990, manufacturers must pay certain statutorily-prescribed rebates on Medicaid purchases for reimbursement on prescription drugs under state Medicaid plans. Federal Medicaid reimbursement for drug products of original NDA-holders is denied if less expensive generic versions are available from other manufacturers. In addition, the Federal government follows a diagnosis related group ("DRG") payment system for certain institutional services provided under Medicare or Medicaid. The DRG system entitles a health care facility to a fixed reimbursement based on discharge diagnoses rather than actual costs incurred in patient treatment, thereby increasing the incentive for the facility to limit or control expenditures for many health care products.
Under the Prescription Drug User Fee Act of 1992, the FDA has imposed fees on various aspects of the approval, manufacture and sale of prescription drugs. The Company expects that a number of competing healthcare reform proposals will be introduced and debated which may be highly regulatory and affect the marketing of prescription drug products. The Company cannot predict the outcome or effect on the marketing of prescription drug products of the legislative and political process.
Principal Customers
McKesson Drug Company, Bergen Brunswig Corp., Cardinal Distributors, Inc. and Amerisource Corp., national drug wholesalers, accounted for 22%, 11%, 17% and 12%, respectively, of Forest's net sales for the fiscal year ended March 31, 2001 and 19%, 14% 13% and 12%, respectively, of Forest's net sales for the fiscal year ended March 31, 2000. For the fiscal year ended March 31, 1999, McKesson Drug Company, Bergen Brunswig Corp. and Cardinal Distributors, Inc. accounted for 17%, 12% and 14%, respectively, of Forest's net sales. No other customer accounted for 10% or more of Forest's net sales for those fiscal years.
Environmental Standards
Forest anticipates that the effects of compliance with federal, state and local laws and regulations relating to the discharge of materials into the environment will not have any material effect on capital expenditures, earnings or the competitive position of Forest.
Raw Materials
The principal raw materials used by Forest for its various products are purchased in the open market. Most of these materials are obtainable and available from several sources in the United States and elsewhere in the world, although the Company's most important products, including Celexa, contain patented or other exclusively manufactured materials available from only a single source. Forest has not experienced any significant shortages in supplies of such raw materials.
Product Liability Insurance
Forest currently maintains $150 million of product liability coverage per "occurrence" and in the aggregate. Although in the past there have been product liability claims asserted against Forest, none for which Forest has been found liable, there can be no assurance that all potential claims which may be asserted against Forest in the future would be covered by Forest's present insurance.
Research and Development
During the fiscal year ended March 31, 2001, Forest spent $105,706,000 for research and development, as compared to $70,292,000 and $51,641,000 in the fiscal years ended March 31, 2000 and 1999, respectively. Included in research and development expense are payments made pursuant to licensing agreements for new product opportunities where safety and efficacy have not yet been demonstrated and accordingly payments made in connection with acquiring the product rights are charged to research and development. Forest's research and development expenditures consist primarily of the conduct of clinical studies required to obtain approval of new products.
Employees
At March 31, 2001, Forest had a total of 2,826 employees.
Patents and Trademarks
Forest owns or licenses certain United States and foreign patents on many of its branded products and products in development, including, but not limited to, Aerobid, Tiazac, Cervidil®, Monurol®, Synapton™, Flumadine®, Forest's licensed oxycodone/ ibuprofen analgesic, and memantine, lercandipine, dexloxiglumide, neramexane, gaboxadol and other compounds under development pursuant to license arrangements(see "Recent Developments"), which patents expire through 2014. While no longer subject to patent protection, Celexa enjoys legal marketing exclusivity in the United States under the Waxman-Hatch Act until 2003. The escitalopram compound is covered by a United States patent which expires in 2009. Forest believes these patents and other rights are or may become of significant benefit to its business. Additionally, Forest owns and licenses certain United States patents, and has pending United States and foreign patent applications, relating to various aspects of its Synchron® technology and to other controlled release technology, which patents expire through 2008. Forest believes that these patents are useful in its business, however, there are numerous patents and unpatented technologies owned by others covering other controlled release processes.
Forest owns various trademarks and trade names which it believes are of significant benefit to its business.
Backlog -- Seasonality
Backlog of orders is not considered material to Forest's business prospects. Forest's business is not seasonal in nature.
ITEM 2. PROPERTIES
Forest owns a 150,000 square foot building on 28 acres in Commack, New York. This facility is used for packaging, warehousing, administration and sales training. In addition, Forest owns additional buildings of 100,000 and 20,000 square feet in Commack, New York and is developing these locations as a research and development complex which is expected to become operational in fiscal 2003.
Forest also owns five buildings and leases two buildings in and around Inwood, Long Island, New York, containing a total of approximately 145,000 square feet. The buildings are used for manufacturing, research and development, warehousing and administration. In addition, Forest leases approximately 32,000 square feet in Farmingdale, New York for use as a clinical laboratory testing facility and leases an additional 105,000 square foot warehouse and administrative office facility in Hauppauge, New York.
Forest also leases approximately 47,000 square feet of office space in Jersey City, New Jersey, which is used by certain of its scientific and regulatory personnel. Forest has also leased 72,000 square feet in a building which will be operational in 2002, and will be used for its scientific affairs department.
Forest Pharmaceuticals, Inc. ("FPI"), a wholly owned subsidiary of the Company, owns two facilities in Cincinnati, Ohio aggregating approximately 108,000 square feet. In St. Louis, Missouri, FPI owns a 330,000 square foot facility on 26 acres of land. This facility is being used for warehousing, distribution and administration. In addition, FPI owns a facility of 22,000 square feet in St. Louis, Missouri. This facility is used for manufacturing.
Pharmax owns an approximately 95,000 square foot complex in the London suburb of Bexley, England, which houses its plant and administrative and central marketing offices.
Forest's Tosara subsidiary owns an 18,000 square foot manufacturing and distribution facility located in an industrial park in Dublin, Ireland. Forest Ireland, a subsidiary of Forest, owns an approximately 130,000 square foot manufacturing and distribution facility located in Dublin, Ireland. The facility is currently used principally for the manufacture of and distribution to the United States of Celexa tablets. Forest expanded this facility in fiscal 2000.
Forest presently leases approximately 120,000 square feet of executive office space at 909 Third Avenue, New York, New York. The lease expires in 2010, subject to 2 five year renewal options.
Management believes that the above-described properties are sufficient for Forest's present and anticipated needs.
Net rentals for leased space for the fiscal year ended March 31, 2001 aggregated approximately $5,427,000 and for the fiscal year ended March 31, 2000 aggregated approximately $3,339,000.
ITEM 3. LEGAL PROCEEDINGS
The Company remains a defendant in actions filed in various federal district courts alleging certain violations of the federal anti-trust laws in the marketing of pharmaceutical products. In each case, the actions were filed against many pharmaceutical manufacturers and suppliers and allege price discrimination and conspiracy to fix prices in the sale of pharmaceutical products. The actions were brought by various pharmacies (both individually and, with respect to certain claims, as a class action) and seek injunctive relief and monetary damages. The Judicial Panel on Multi-District Litigation has ordered these actions coordinated (and, with respect to those actions brought as class actions, consolidated) in the Federal District Court for the Northern District of Illinois (Chicago) under the caption "In re Brand Name Prescription Drugs Antitrust Litigation."
On November 30, 1998, the defendants remaining in the consolidated federal class action (which proceeded to trial beginning in September 1998), including the Company, were granted a directed verdict by the trial court after the plaintiffs had concluded their case. In ruling in favor of the defendants, the trial judge held that no reasonable jury could reach a verdict in favor of the plaintiffs and stated "the evidence of conspiracy is meager, and the evidence as to individual defendants paltry or non-existent." The Court of Appeals for the Seventh Circuit subsequently affirmed the granting of the directed verdict in the federal class case in favor of the Company.
Following the Seventh Circuit's affirmance of the directed verdict in favor of the Company, the Company has secured the voluntary dismissal of the conspiracy allegations contained in all of the federal cases brought by individual plaintiffs who elected to "opt-out" of the federal class action, which cases were included in the coordinated proceedings, as well as the dismissal of similar conspiracy and price discrimination claims pending in various state courts. The Company, together with other manufacturers, remains a defendant in many of the federal opt-out cases included in the coordinated proceedings to the extent of claims alleging price discrimination in violation of the Robinson-Patman Act. While no discovery or other significant proceedings have been taken to date in respect of such claims, there can be no assurance that the Company will not be required to actively defend such claims or to pay substantial amounts to dispose of such claims.
The Company is a defendant in an action pending in Federal District Court for the Northern District of Illinois entitled G.D. Searle & Co. v. Forest Laboratories, Inc.. Plaintiff G.D. Searle asserts claims for federal and common law trademark infringement in respect to rights Searle alleges as to the name "Celebra" and arising from the marketing of Celexa. The action seeks injunctive relief and unspecified monetary damages. Discovery is expected to be completed during the fall of 2001; no date for trial has yet been set. The Company believes this action is without merit.
The Company is not subject to any other pending legal proceedings, other than ordinary routine claims incidental to its business.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE
OF SECURITY HOLDERS
Not Applicable.
PART II
ITEM 5. MARKET FOR REGISTRANT'S COMMON
EQUITY AND RELATED STOCKHOLDER
MATTERS
The information required by this item is incorporated by reference to page 34 of the Annual Report.
Forest has never paid cash dividends on its Common Stock and does not expect to pay such dividends in the foreseeable future. Management presently intends to retain all available funds for the development of its business and for use as working capital. Future dividend policy will depend upon Forest's earnings, capital requirements, financial condition and other relevant factors.
ITEM 6. SELECTED FINANCIAL DATA
The information required by this item is incorporated by reference to page 20 of the Annual Report.
ITEM 7. MANAGEMENT'S DISCUSSION AND
ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS
The information required by this item is incorporated by reference to pages 18 and 19 of the Annual Report.
ITEM 7A. QUANTITATIVE AND QUALITATIVE
DISCLOSURES ABOUT MARKET RISK
The information required by this item is incorporated by reference to page 19 of the Annual Report.
ITEM 8. FINANCIAL STATEMENTS AND
SUPPLEMENTARY DATA
The information required by this item is incorporated by reference to pages 21 through 33 of the Annual Report.
ITEM 9. CHANGES IN AND DISAGREEMENTS
WITH ACCOUNTANTS ON ACCOUNTING
AND FINANCIAL DISCLOSURE
Not Applicable.
PART III
In accordance with General Instruction G(3), the information called for by Part III (Items 10 through 13) is incorporated by reference from Forest's definitive proxy statement to be filed pursuant to Regulation 14A promulgated under the Securities Exchange Act of 1934 in connection with Forest's 2001 Annual Meeting of Shareholders.
PART IV
ITEM 14. |
EXHIBITS, FINANCIAL STATEMENT SCHEDULES |
||||||
|
|||||||
|
(a) |
1. |
Financial statements. The following consolidated financial statements of Forest Laboratories, Inc. and Subsidiaries included in the Annual Report are incorporated by reference herein in Item 8: |
||||
|
Report of Independent Certified Public Accountants |
||||||
|
Consolidated balance sheets - |
||||||
|
|||||||
|
Consolidated statements of income - |
||||||
|
|||||||
|
Consolidated statements of comprehensive income - |
||||||
|
|||||||
|
Consolidated statements of shareholders' equity - |
||||||
|
|||||||
|
Consolidated statements of cash flows - |
||||||
|
|||||||
|
Notes to consolidated financial statements |
||||||
|
2. |
Financial statement schedules. The following consolidated financial statement schedules of Forest Laboratories, Inc. and Subsidiaries are included herein: |
|||||
Report of Independent Certified Public Accountants |
S-1 |
||||||
Schedule II |
Valuation and qualifying accounts |
S-2 |
|||||
|
|
|
|||||
All other schedules for which provision is made in the applicable accounting regulations of the |
|||||||
|
(b) |
|
Forest filed a report on Form 8-K on January 4, 2001 to report a two-for-one stock split, effected in the form of a 100% stock dividend. |
||||
|
3. |
Exhibits: |
|||||
|
(3)(a) |
Articles of Incorporation of Forest, as amended. Incorporated by reference from the Current Report on Form 8-K dated March 9, 1981 filed by Forest, from Registration Statement on Form S-1 (Registration No. 2-97792) filed by Forest on May 16, 1985, from Forest's definitive proxy statement filed pursuant to Regulation 14A with respect to Forest's 1987, 1988 and 1993 Annual Meetings of Shareholders and from the Current Report on Form 8-K dated March 15, 1988. |
|||||
|
|||||||
|
(3)(b) |
By-laws of Forest. Incorporated by reference to Forest's Current Report on Form |
|||||
|
|||||||
|
(10) |
Material Contracts |
|||||
|
10.1 |
Benefit Continuation Agreement dated as of December 1, 1989 between Forest and Howard Solomon. Incorporated by reference to Forest's Annual Report on Form 10-K for the fiscal year ended March 31, 1990 (the "1990 l0-K"). |
|||||
|
10.2 |
Benefit Continuation Agreement dated as of May 27, 1990 between Forest and Kenneth E. Goodman. Incorporated by reference to the 1990 10-K. |
|||||
|
10.3 |
Benefit Continuation Agreement dated as of April 1, 1995 between Forest and Phillip M. Satow. Incorporated by reference to Forest's Annual Report on Form 10-K for the fiscal year ended March 31, 1995 (the "1995 10-K"). |
|||||
|
10.4 |
Split Dollar Life Insurance Agreement dated March 29, 1994 between Forest and Howard Solomon. Incorporated by reference to Forest's Annual Report on Form 10-K for the fiscal year ended March 31, 1994 (the "1994 10-K"). |
|||||
|
10.6 |
Split Dollar Life Insurance Agreement dated March 29, 1994 between Forest and Kenneth E. Goodman. Incorporated by reference to the 1994 10-K. |
|||||
|
10.7 |
Employment Agreement dated as of September 30, 1994 by and between Forest and Howard Solomon. Incorporated by reference to 1995 10-K. |
|||||
|
10.8 |
Employment Agreement dated as of September 30, 1994 by and between Forest and Kenneth E. Goodman. Incorporated by reference to the 1995 10-K. |
|||||
|
10.9 |
Employment Agreement dated as of October 24, 1995 by and between Forest and Dr. Lawrence S. Olanoff. Incorporated by reference to Forest's Annual Report on Form 10-K for the fiscal year ended March 31, 1996 (the "1996 10-K"). |
|||||
|
10.10 |
Employment Agreement dated June 24, 1998 between Forest and Elaine Hochberg. Incorporated by reference to Forest's Annual Report on Form 10-K for the fiscal year ended March 31, 1998 (the "1998 10-K"). |
|||||
|
10.11 |
Employment Agreement dated June 21, 1999 between Forest and John E. Eggers. Incorporated by reference to Forest's Annual Report on Form 10-K for the fiscal year ended March 31, 1999 (the "1999 10-K"). |
|||||
|
10.12 |
Employment Agreement dated January 16, 1995 between Forest and Mary Prehn. Incorporated by reference to the 1998 10-K. |
|||||
|
10.13 |
Employment Agreement dated November 22, 2000 between Forest and Charles E. Triano. |
|||||
|
10.14 |
License Agreement dated September 11, 1995 between Biovail Corporation International and Forest. Incorporated by reference to Exhibit No. (C)(2) to Schedule 14D-1 of Forest dated September 18, 1995. |
|||||
|
10.15 |
License and Supply Agreement dated October 3, 1995 between Forest Laboratories (Ireland) Limited and H. Lundbeck A/S. Incorporated by reference to the 1999 10-K. |
|||||
|
13 |
Portions of the Registrant's Annual Report to Stockholders. |
|||||
|
22 |
List of Subsidiaries. Incorporated by reference to Exhibit 22 to the 1988 10-K. |
|||||
|
23 |
Consent of BDO Seidman, LLP. |
SIGNATURES
Pursuant to the requirements of Section 13 and 15(d) of the Securities Exchange Act of 1934, Forest has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Dated: June 28, 2001
|
FOREST LABORATORIES, INC. |
|
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of Forest and in the capacities and on the dates indicated.
PRINCIPAL EXECUTIVE |
||
/s/ Howard Solomon |
Chairman of the |
June 28, 2001 |
/s/ Kenneth E. Goodman |
President, Chief |
June 28, 2001 |
PRINCIPLE FINANCIAL |
||
/s/ John E. Eggers |
Vice President - |
June 28, 2001 |
DIRECTORS: |
|
|
/s/ Phillip M. Satow |
Director |
June 28, 2001 |
/s/ George S. Cohan |
Director |
June 28, 2001 |
/s/ William J. Candee, III |
Director |
June 28, 2001 |
/s/ Dan L. Goldwasser |
Director |
June 28, 2001 |
/s/ Lester B. Salans |
Director |
June 28, 2001 |
REPORT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS
Board of Directors and Shareholders
Forest Laboratories, Inc.
The audits referred to in our report dated April 20, 2001 relating to the consolidated financial statements of Forest Laboratories Inc. and Subsidiaries, which is referred to in Item 8 of this Form 10-K, include the audits of the accompanying financial
statement schedule. This financial statement schedule is the responsibility of the Company's management. Our responsibility is to express an opinion of this financial statement schedule based on our audits.
In our opinion, such financial statement schedule presents fairly, in all material respects, the information set forth therein.
/s/ BDO Seidman, LLP
BDO Seidman, LLP
New York, New York
April 20, 2001
S-1
|
|
|
|
|
|
|
SCHEDULE II |
|
||||
FOREST LABORATORIES, INC. AND SUBSIDIARIES
|
||||||||||||
Column A |
Column B |
|
Column C |
|
Column D |
|
Column E |
|
||||
|
Balance |
|
|
|
|
|
Balance |
|
||||
|
|
|
|
|
|
|
|
|
||||
Year ended March 31, 2001: |
|
|
|
|
|
|
|
|
||||
|
|
|
|
|
|
|
|
|
||||
Allowance for doubtful accounts |
$ 7,936,000 |
|
$ 3,623,000 |
|
$ 436,000 |
(i) |
$11,123,000 |
|
||||
Allowance for cash discounts |
6,078,000 |
|
34,555,000 |
|
31,968,000 |
(ii) |
8,665,000 |
|
||||
Inventory reserve |
14,001,000 |
|
2,145,000 |
|
3,197,000 |
(i) |
12,949,000 |
|
||||
|
|
|
|
|
|
|
|
|
||||
Year ended March 31, 2000: |
|
|
|
|
|
|
|
|
||||
|
|
|
|
|
|
|
|
|
||||
Allowance for doubtful accounts |
$10,314,000 |
|
$ 3,830,000 |
|
$ 6,208,000 |
(i) |
$ 7,936,000 |
|
||||
Allowance for cash discounts |
6,380,000 |
|
22,996,000 |
|
23,298,000 |
(ii) |
6,078,000 |
|
||||
Inventory reserve |
13,911,000 |
|
8,273,000 |
|
8,183,000 |
(i) |
14,001,000 |
|
||||
|
|
|
|
|
|
|
|
|
||||
Year ended March 31, 1999: |
|
|
|
|
|
|
|
|
||||
|
|
|
|
|
|
|
|
|
||||
Allowance for doubtful accounts |
$ 9,817,000 |
|
$ 1,750,000 |
|
$ 1,253,000 |
(i) |
$10,314,000 |
|
||||
Allowance for cash discounts |
5,878,000 |
|
14,903,000 |
|
14,401,000 |
(ii) |
6,380,000 |
|
||||
Inventory reserve |
11,131,000 |
|
7,706,000 |
|
4,926,000 |
(i) |
13,911,000 |
|
||||
|
|
|
|
|
|
|
|
|
||||
(i) Represents actual amounts written off. |
||||||||||||
(ii) Represents cash discounts given. |
S-2
EXHIBIT 10.13
EMPLOYMENT AGREEMENT |
||||||||
|
||||||||
AGREEMENT by and between FOREST LABORATORIES, INC. Company, a Delaware corporation (the "Company") and Charles E. Triano (the "Executive"), dated as of the 22nd day of the eleventh month of 2000. |
||||||||
The Board of Directors of the Company (the "Board") has determined that it is in the best interests of the Company and its shareholders to assure that the Company will have the continued dedication of the Executive, notwithstanding the possibility,
threat or occurrence of a Change of Control (as defined below) of the Company. The Board believes it is imperative to diminish the inevitable distraction of the Executive by virtue of the personal uncertainties and risks created by a pending or threatened
Change of Control and to encourage the Executive's full attention and dedication to the Company currently and in the event of any threatened or pending Change of Control, and to provide the Executive with compensation and benefits arrangements upon a
Change of Control which ensure that the compensation and benefits expectations of the Executive will be satisfied and which are competitive with those of other corporations. Therefore, in order to accomplish these objectives, the Board has caused the
Company to enter into this Agreement. |
||||||||
|
||||||||
NOW, THEREFORE, IT IS HEREBY AGREED AS FOLLOWS: |
||||||||
|
||||||||
1. |
Certain Definitions: |
|||||||
(a) |
The "Effective Date" shall mean the first date during the Change of Control Period (as defined in Section 1(b) on which a Change of Control (as defined in Section 2) occurs. Anything in this Agreement to the contrary notwithstanding, if a Change of
Control occurs and if the Executive's employment with the Company is terminated prior to the date on which the Change of Control occurs, and if it is reasonably demonstrated by the Executive that such termination of employment (i) was at the request of a
third party who has taken steps reasonably calculated to effect a Change of Control or (ii) otherwise arose in connection with or anticipation of a Change of Control, then for all purposes of this Agreement the "Effective Date" shall mean the date
immediately prior to the date of such termination of employment. |
|||||||
(b) |
The "Change of Control Period" shall mean the period commencing on the date hereof and ending on the third anniversary of the date hereof; provided, however, that commencing on the date one year after the date hereof, and on each annual anniversary of
such date (such date and each annual anniversary thereof shall be hereinafter referred to as the "Renewal Date"), unless previously terminated, the Change of Control Period shall be automatically extended so as to terminate three years from such Renewal
Date, unless at least 60 days prior to the Renewal Date the Company shall give notice to the Executive that the Change of Control Period shall not be so extended. |
|||||||
2. |
Change of Control. For the purpose of this Agreement, a "Change of Control" shall mean: |
|||||||
(a) |
The acquisition by any individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")) (a "Person") of beneficial ownership (within the meaning of Rule 13d-3
promulgated under the Exchange Act) of 20% or more of either (i) the then outstanding shares of common stock of the Company (the "Outstanding Company Common Stock") or (ii) the combined voting power of the then outstanding voting securities of the Company
entitled to vote generally in the election of directors (the "Outstanding Company Voting Securities"); provided, however, that for purposes of this subsection (a), the following acquisitions shall not constitute a Change of Control: (i) any acquisition
directly from the Company, (ii) any acquisition by the Company, (iii) any acquisition by any employee benefit plan (or related trust) sponsored or maintained by the Company or any corporation controlled by the Company or (iv) any acquisition by any
corporation pursuant to a transaction which complies with clauses (i), (ii) and (iii) of subsection (c) of this Section 2; or |
|||||||
(b) |
Individuals who, as of the date hereof, constitute the Board (the "Incumbent Board") cease for any reason to constitute at least a majority of the Board; provided, however, that any individual becoming a director subsequent to the date hereof whose
election, or nomination for election by the Company's shareholders, was approved by a vote of at least a majority of the directors then comprising the Incumbent Board shall be considered as though such individual were a member of the Incumbent Board, but
excluding for this purpose, any such individual whose initial assumption of office occurs as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or
consents by or on behalf of a Person other than the Board; or |
|||||||
(c) |
Consummation of a reorganization, merger or consolidation or sale or other disposition of all or substantially all of the assets of the Company (a "Business Consolidation"), in each case, unless, following such Business Combination, (i) all or
substantially all of the individuals and entities who were the beneficial owners, respectively, of the Outstanding Company Common Stock and Outstanding Voting Securities immediately prior to such Business Combination beneficially own, directly or
indirectly, more than 50% of, respectively, the then outstanding shares of common stock and the combined voting power of the then outstanding voting securities entitled to vote generally in the election of directors, as the case may be, of the corporation
resulting from such Business Combination (including, without limitation, a corporation which as a result of such transaction owns the Company or all or substantially all of the Company's assets either directly or through one or more subsidiaries) in
substantially the same proportions as their ownership, immediately prior to such Business Combination of the Outstanding Company Common Stock and Outstanding Company Voting Securities, as the case may be, (ii) no Person (excluding any corporation
resulting from such Business Combination or any employee benefit plan (or related trust) of the Company or such corporation resulting from such Business Combination) beneficially owns, directly or indirectly, 20% or more of, respectively, the then
outstanding shares of common stock of the corporation resulting from such Business Combination or the combined voting power of the then outstanding voting securities of such corporation except to the extent that such ownership existed prior to the
Business Combination and (iii) at least a majority of the members of the board of directors of the corporation resulting from such Business Combination were members of the Incumbent Board at the time of the execution of the initial agreement, or of the
action of the Board, providing such Business Combination; or |
|||||||
(d) |
Approval by the shareholders of the Company of a complete liquidation or dissolution of the Company. |
|||||||
3. |
Employment Period. The Company hereby agrees to continue the Executive in its employ, and the Executive hereby agrees to remain in the employ of the Company subject to the terms and conditions of this Agreement, for the period commencing on the
Effective Date and ending on the third anniversary of such date (the "Employment Period"). |
|||||||
4. |
Terms of Employment. |
|||||||
(a) |
Position and Duties. |
|||||||
(i) |
During the Employment Period, (A) the Executive's position (including status, offices, titles and reporting requirements), authority, duties, and responsibilities shall be at least commensurate in all material respects with the most significant of
those held, exercised and assigned at any time during the 120-day period immediately preceding the Effective Date and (B) the Executive's services shall be performed at the location where the Executive was employed immediately preceding the Effective Date
or any office or location less than 35 miles from such location. |
|||||||
(ii) |
During the Employment Period, and excluding any periods of vacation and sick leave to which the Executive is entitled, the Executive agrees to devote reasonable attention and time during normal business hours to the business and affairs of the Company
and, to the extent necessary to discharge the responsibilities assigned to the Executive thereunder, to use the Executive's reasonable best efforts to perform faithfully and efficiently such responsibilities. During the Employment Period it shall not be a
violation of this Agreement for the Executive to (A) serve on corporate, civic or charitable boards or committees, (B) deliver lectures, fulfill speaking engagements or teach at educational institutions and (C) manage personal investments, so long as such
activities do not significantly interfere with the performance of the Executive's responsibilities as an employee of the Company in accordance with this Agreement. It is expressly understood and agreed that to the extent that any such activities have been
conducted by the Executive prior to the Effective Date, the continued conduct of such activities (or the conduct of activities similar in nature and scope thereto) subsequent to the Effective Date shall not thereafter be deemed to interfere with the
performance of the Executives responsibilities to the Company. |
|||||||
(b) |
Compensation. |
|||||||
(i) |
Base Salary. During the Employment Period, the Executive shall receive an annual base salary ("Annual Base Salary"), which shall be paid at a monthly rate, at least equal to twelve times the highest monthly base salary paid or payable,
including any base salary which has been earned but deferred, to the Executive by the Company and its affiliated companies in respect of the twelve-month period immediately preceding the month in which the Effective Date occurs. During the Employment
Period, the Annual Base Salary shall be reviewed no more than 12 months after the last salary increase awarded to the Executive prior to the Effective Date and thereafter at least annually. Any increase in Annual Base Salary shall not serve to limit or
reduce any other obligation to the Executive under this Agreement. Annual Base Salary shall not be reduced after any such increase and the term Annual Base Salary as utilized in this Agreement shall refer to Annual Base Salary as so increased. As used in
this Agreement, the term, "affiliated companies" shall include any company controlled by, controlling or under common control with the Company. |
|||||||
(ii) |
Annual Bonus. In addition to Annual Base Salary, the Executive shall be awarded, for each fiscal year ending during the Employment Period, an annual bonus (the "Annual Bonus") in cash at least equal to the highest aggregate amount awarded to
the Executive under all annual bonus, incentive and other similar plans of the Company with respect to any of the last three full fiscal years prior to the Effective Date (annualized in the event that the Executive was not employed by the Company for the
whole of such fiscal year) (the "Recent Annual Bonus"). Each such Annual Bonus shall be paid no later than the end of the third month of the fiscal year next following the fiscal year for which the Annual Bonus is awarded, unless the Executive shall elect
to defer the receipt of such Annual Bonus. |
|||||||
(iii) |
Incentive, Savings and Retirement Plans. During the Employment Period, the Executive shall be entitled to participate in all incentive, savings and retirement plans, practices, policies and programs applicable generally to other peer executives
of the Company and its affiliated companies, but in no event shall such plans, practices, policies and programs provide the Executive with incentive opportunities (measured with respect to both regular and special incentive opportunities, to the extent,
if any, that such distinction is applicable), savings opportunities and retirement benefit opportunities, in each case, less favorable, in the aggregate, than the most favorable of those provided by the Company and its affiliated companies for the
Executive under such plans, practices and policies and programs as in effect at any time during the 120-day period immediately preceding the Effective Date or if more favorable to the Executive, those provided generally at any time after the Effective
Date to other peer executives of the Company and its affiliated companies. |
|||||||
(iv) |
Welfare Benefit Plans. During the Employment Period, the Executive and/or the Executive's family, as the case may be, shall be eligible for participation in and shall receive all benefits under welfare benefit plans, practices, policies and
programs provided by the Company and its affiliated companies (including, without limitation, medical, prescription, dental, disability, employee life, group life, accidental death and travel accident insurance plans and programs) to the extent applicable
generally to other peer executives of the Company and its affiliated companies, but in no event shall such plans, practices, policies and programs provide the Executive with benefits which are less favorable in the aggregate, than the most favorable of
such plans, practices, policies and programs in effect for the Executive at any time during the 120-day period immediately preceding the Effective Date or, if more favorable to the Executive, those provided generally at any time after the Effective Date
to other peer executives of the Company and its affiliated companies. |
|||||||
(v) |
Expenses. During the Employment Period, the Executive shall be entitled to receive prompt reimbursement for all reasonable expenses incurred by the Executive in accordance with the most favorable policies, practices and procedures of the
Company and its affiliated companies in effect for the Executive at any time during the 120-day period immediately preceding the Effective Date or, if more favorable to the Executive, as is effect generally at any time thereafter with respect to other
peer executives of the Company and its affiliated companies. |
|||||||
(vi) |
Fringe Benefits. During the Employment Period, the Executive shall be entitled to fringe benefits, including, without limitation, tax and financial planning services, payment of club dues, and, if applicable, use of an automobile and payment of
related expenses, in accordance with the most favorable plans, practices, programs and policies of the Company and its affiliated companies in effect for the Executive at any time during the 120-day period immediately preceding the Effective Date or, if
more favorable to the Executive, as in effect generally at any time thereafter with respect to other peer executives of the Company and its affiliated companies. |
|||||||
(vii) |
Office and Support Staff. During the Employment Period, the Executive shall be entitled to an office or offices of a size and with furnishings and other appointments, and to exclusive personal secretarial and other assistance, at least equal to
the most favorable of the foregoing provided to the Executive by the Company and its affiliated companies at any time during the 120-day period immediately preceding the Effective Date or, if more favorable to the Executive, as provided generally at any
time thereafter with respect to other peer executives of the Company and its affiliated companies. |
|||||||
(viii) |
Vacation. During the Employment Period, the Executive shall be entitled to paid vacation in accordance with the most favorable plans, policies, programs and practices of the Company and its affiliated companies as in effect for the Executive at
any time during the 120-day period immediately preceding the Effective Date or, if more favorable to the Executive, as in effect generally at any time thereafter with respect to other peer executives of the Company and its affiliated companies. |
|||||||
5. |
Termination of Employment. |
|||||||
(a) |
Death or Disability. The Executive's employment shall terminate automatically upon the Executive's death during the Employment Period. If the Company determines in good faith that the Disability of the Executive has occurred during the
Employment Period (pursuant to the definition of Disability set forth below), it may give to the Executive written notice in accordance with Section 12(b) of this Agreement of its intention to terminate the Executive's employment. In such event, the
Executive's employment with the Company shall terminate effective on the 30th day after receipt of such notice by the Executive (the "Disability Effective Date"), provided that, within 30 days after such receipt, the Executive shall not have returned to
full-time performance of the Executive's duties. For purposes of this Agreement, "Disability" shall mean the absence of the Executive from the Executive's duties with the Company on a full-time basis for 180 consecutive business days as a result of
incapacity due to mental or physical illness which is determined to be total and permanent by a physician selected by the Company or its insurers and acceptable to the Executive or the Executive's legal representative. |
|||||||
(b) |
Cause. The Company may terminate the Executive's employment during the Employment Period for Cause. For purposes of this Agreement, "Cause" shall mean: |
|||||||
(i) |
the willful and continues failure of the Executive to perform substantially the Executive's duties with the Company or one of its affiliates (other than any such failure resulting from incapacity due to physical or mental illness), after a written
demand for substantial performance is delivered to the Executive by the Board or the Chief Executive Officer of the Company which specifically identifies the manner in which the Board or Chief Executive Officer believes that the Executive has not
substantially performed the Executive's duties, or |
|||||||
(ii) |
the willful engaging by the Executive in illegal conduct or gross misconduct which is naturally and demonstrably injurious to the Company. |
|||||||
For purposes of this provision, no act or failure to act, on the part of the Executive, shall be considered "willful, unless it is done, or omitted to be done, by the Executive in bad faith or without reasonable belief that the Executive's action or
omission was in the best interests of the Company. Any act, or failure to act, based upon authority given pursuant to a resolution duly adopted by the Board or upon the instructions of the Chief Executive Officer or a senior officer of the Company or
based upon the advice of counsel for the Company shall be conclusively presumed to be done, or omitted to be done, by the Executive in good faith and in the best interests of the Company. The cessation of employment of the Executive shall not be deemed to
be for Cause unless and until there shall have been delivered to the Executive a copy of a resolution duly adopted by the affirmative vote of not less than three-quarters of the entire membership of the Board at a meeting of the Board called and held for
the purpose (after reasonable notice is provided to the Executive and the Executive is given an opportunity, together with counsel, to be heard before the Board), finding that, in the good faith opinion of the Board, the Executive is guilty of the conduct
described in subparagraph (i) or (ii) above, and specifying the particulars thereof in detail. |
||||||||
(c) |
Good Reason. The Executive's employment may be terminated by the Executive for Good Reason. For purposes of this Agreement, "Good Reason" shall mean: |
|||||||
(i) |
the assignment to the Executive of any duties inconsistent in any respect with the Executive's position (including status, offices, titles and reporting requirements), authority, duties or responsibilities as contemplated by Section 4(a) of this
Agreement, or any other action by the Company which results in a diminution in such position, authority, duties or responsibilities, excluding for this purpose an isolated, insubstantial and inadvertent action not taken in bad faith and which is remedied
by the Company promptly after receipt of notice thereof given by the Executive; |
|||||||
(ii) |
any failure by the Company to comply with any of the provisions of Section 4(b) of this Agreement, other than an isolated, insubstantial and inadvertent failure not occurring in bad faith and which is remedied by the Company promptly after receipt of
notice thereof given by the Executive; |
|||||||
(iii) |
the Company's requiring the Executive to be based at any office or location other than as provided in Section 4(a)(i)(B) hereof or the Company's requiring the Executive to travel on Company business to a substantially greater extent than required
immediately prior to the Effective Date; |
|||||||
(iv) |
any purported termination by the Company of the Executive's employment otherwise than as expressly permitted by this Agreement; or |
|||||||
(v) |
any failure by the Company to comply with and satisfy Section 11(c) of this Agreement. |
|||||||
For purposes of this Section 5(c), any good faith determination of "Good Reason" made by the Executive shall be conclusive. Anything in this Agreement to the contrary notwithstanding, a termination by the Executive for any reason during the 30-day
period immediately following the first anniversary of the Effective Date shall be deemed to be a termination for Good Reason for all purposes of this Agreement. |
||||||||
(d) |
Notice of Termination. Any termination by the Company for Cause, or by the Executive for Good Reason, shall be communicated by Notice of Termination to the other party hereto given in accordance with Section 12(b) of this Agreement. For
purposes of this Agreement, a "Notice of Termination" means a written notice which (i) indicates the specific termination provision in this Agreement relied upon, (ii) to the extent applicable, sets forth in reasonable detail the facts and circumstances
claimed to provide a basis for termination of the Executive's employment under the provision so indicated and (iii) if the Date of Termination (as defined below) is other than the date of receipt of such notice, specifies the termination date (which date
shall be not more than thirty days after the giving of such notice). The failure by the Executive or the Company to set forth in the Notice of Termination any fact or circumstance which contributes to a showing of Good Reason or Cause shall not waive any
right of the Executive or the Company, respectively, hereunder or preclude the Executive or the Company, respectively, from asserting such fact or circumstance in enforcing the Executive's or the Company's rights hereunder. |
|||||||
(e) |
Date of Termination. "Date of Termination" means (i) if the Executive's employment is terminated by the Company for Cause, or by the Executive for Good Reason, the date of receipt of the Notice of Termination or any later date specified
therein, as the case may be, (ii) if the Executive's employment is terminated by the Company other than for Cause or Disability, the Date of Termination shall be the date on which the Company notifies the Executive of such termination and (iii) if the
Executive's employment is terminated by reason of death or Disability, the Date of Termination shall be the date of death of the Executive or the Disability Effective Date, as the case may be. |
|||||||
6. |
Obligations of the Company upon Termination. |
|||||||
(a) |
Good Reason: Other Than for Cause, Death or Disability. If, during the Employment Period, the Company shall terminate the Executive's employment other than for Cause or Disability or the Executive shall terminate employment for Good Reason: |
|||||||
(i) |
the Company shall pay to the Executive in a lump sum in cash within 30 days after the Date of Termination the aggregate of the following amounts: |
|||||||
A. |
the sum of (1) the Executive's Annual Base Salary through the Date of Termination to the extent not theretofore paid, (2) the product of (x) the higher of (i) the Recent Annual Bonus and (II) the Annual Bonus paid or payable, including any bonus or
portion thereof which has been earned but deferred (and annualized for any fiscal year consisting of less than twelve full months or during which the Executive was employed for less than twelve full months), for the most recently completed fiscal year
during the Employment Period, if any (such higher amount being referred to as the "Highest Annual Bonus") and (y) a fraction, the numerator of which is the number of days in the current fiscal year through the Date of Termination, and the denominator of
which is 365 and (3) any compensation previously deferred by the Executive (together with any accrued interest of earnings thereon) and any accrued vacation pay, in each case to the extent not theretofore paid (the sum of the amounts described in clauses
(1), (2) and (3) shall be hereinafter referred to as the "Accrued Obligations); and |
|||||||
B. |
the amount equal to the product of (1) three and (2) the sum of (x) the Executive's Annual Base Salary and (y) the Highest Annual Bonus; and |
|||||||
C. |
an amount equal to the excess of (a) the actuarial equivalent of the benefit under the Company's qualified defined benefit retirement plan (the "Retirement Plan") (utilizing actuarial assumptions no less favorable to the Executive than those in effect
under the Company's Retirement Plan immediately prior to the Effective Date), and any excess or supplemental retirement plan in which the Executive participates (together, the "SERP") which the Executive would receive if the Executive's employment
continued for three years after the Date of Termination assuming for this purpose that all accrued benefits are fully vested, and, assuming that the Executive's compensation in each of the three years is that required by Section 4(b)(i) and Section
4(b)(ii), over (b) the actuarial equivalent of the Executive's actual benefit (paid or payable), if any, under the Retirement Plan and the SERP as of the Date of Termination. |
|||||||
(ii) |
for three years after the Executive's Date of Termination, or such longer period as may be provided by the terms of the appropriate plan, program, practice or policy, the Company shall continue benefits to the Executive and/or the Executive's family
at least equal to those which would have been provided to them in accordance with the plans, programs, practices and policies described in Section 4(b)(iv) of this Agreement if the Executive's employment had not been terminated or, if more favorable to
the Executive, as in effect generally at any time thereafter with respect to other peer executives of the Company and its affiliated companies and their families, provided, however, that if the Executive becomes re-employed with another employer provided
plan, the medical and other welfare benefits described herein shall be secondary to those provided under such other plan during such applicable period of eligibility. For purposes of determining eligibility (but not the time of commencement of benefits)
of the Executive for retiree benefits pursuant to such plans, practices, programs and policies, the Executive shall be considered to have remained employed until three years after the Date of Termination and to have retired on the last day of such period; |
|||||||
(iii) |
the Company shall, at its sole expense as incurred, provide the Executive with outplacement services the scope and provider of which shall be selected by the Executive in his sole discretion; and |
|||||||
(iv) |
to the extent not theretofore paid or provided, the Company shall timely pay or provide to the Executive any other amounts or benefits required to be paid or provided or which the Executive is eligible to receive under any plan, program, policy or
practice or contract or agreement of the Company and its affiliated companies (such other amounts and benefits shall be hereinafter referred to as the "Other Benefits"). |
|||||||
(b) |
Death. If the Executive's employment is terminated by reason of the Executive's death during the Employment Period, this Agreement shall terminate without further obligations to the Executive's legal representatives under this Agreement other
than for payment of Accrued Obligations and the timely payment or provision of Other Benefits. Accrued Obligations shall be paid to the Executive's estate or beneficiary, as applicable, in a lump sum in cash within 30 days of the Date of Termination. With
respect to the provision of Other Benefits, the term Other Benefits as utilized in this Section 6(b) shall include, without limitation, and the Executive's estate and/or beneficiaries shall be entitled to receive, benefits at least equal to the most
favorable benefits provided by the Company and affiliated companies to the estates and beneficiaries of peer executives of the Company and such affiliated companies under such plans, programs, practices and policies relating to death benefits, if any, as
in effect with respect to other peer executives and their beneficiaries at any time during the 120-day period immediately preceding the Effective Date or, if more favorable to the Executive's estate and/or the Executive's beneficiaries as in effect on the
date of the Executive's death with respect to other peer executives of the Company and its affiliated companies and their beneficiaries. |
|||||||
(c) |
Disability. If the Executive's employment is terminated by reason of the Executive's Disability during the Employment Period, this Agreement shall terminate without further obligations to the Executive, other than for payment of Accrued
Obligations and the timely payment or provision of Other Benefits. Accrued Obligations shall be paid to the Executive in a lump sum in cash within 30 days of the Date of Termination. With respect to the provision of other Benefits, the term Other Benefits
as utilized in this Section 6(c) shall include, and the Executive shall be entitled after the Disability Effective Date to receive, disability and other benefits at least equal to the most favorable of those generally provided by the Company and its
affiliated companies to disabled executives and/or their families in accordance with such plans, programs, practices and policies relating to disability, if any, as in effect generally with respect to other peer executives and their families at any time
during the 120-day period immediately preceding Effective Date or, if more favorable to the Executive and/or the Executive's family, as in effect at any time thereafter generally with respect to other peer executives of the Company and its affiliated
companies and their families. |
|||||||
(d) |
Cause: Other than for Good Reason. If the Executive's employment shall be terminated for Cause during the Employment Period, this Agreement shall terminate without further obligations to the Executive other than the obligation to pay to the
Executive (x) his Annual Base Salary through the Date of Termination, (y) the amount of any compensation previously deferred by the Executive, and (z) Other Benefits, in each case to the extent theretofore unpaid. If the Executive voluntarily terminates
employment during the Employment Period, excluding a termination for Good Reason, this Agreement shall terminate without further obligations to the Executive, other than for Accrued Obligations and the timely payment of provision of Other Benefits. In
such case, all Accrued Obligations shall be paid to the Executive in a lump sum in cash within 30 days of the Date of Termination. |
|||||||
7. |
Non-exclusivity of Rights. Nothing in this Agreement shall prevent or limit the Executive's continuing or future participation in any plan, program, policy or practice provided by the Company or any of its affiliated companies and for which the
Executive may qualify, nor, subject to Section 12(f), shall anything herein limit or otherwise affect such rights as the Executive may have under any contract or agreement with the Company or any of its affiliated companies. Amounts which are vested
benefits or which the Executive is otherwise entitled to receive under any plan, policy, practice or program of or any contract or agreement with the Company or any of its affiliated companies at or subsequent to the Date of Termination shall be payable
in accordance with such plan, policy, practice or program or contract or agreement except as explicitly modified by this Agreement. |
|||||||
8. |
Full Settlement. The Company's obligation to make the payments provided for in this Agreement and otherwise to perform its obligations hereunder shall not be affected by any set-off, counterclaim, recoupment, defense or other claim, right or
action which the Company may have against the Executive or others. In no event shall the Executive be obligated to seek other employment or take any other action by way of mitigation of the amounts payable to the Executive under any of the provisions of
this Agreement and such amounts shall not be reduced whether or not the Executive obtains other employment. The Company agrees to pay as incurred, to the full extent permitted by law, all legal fees and expenses which the Executive may reasonably incur as
a result of any contest (regardless of the outcome thereof) by the Company, the Executive or others of the validity or enforceability of, or liability under, any provision of this Agreement or any guarantee of performance thereof (including as a result of
any contest by the Executive about the amount of any payment pursuant to this Agreement), plus in each case interest on any delayed payment at the applicable Federal rate provided for in Section 7872(f)(2)(A) of the Internal Revenue Code of 1986, as
amended (the "Code"). |
|||||||
9. |
Certain Reductions of Payments. |
|||||||
(a) |
Anything in this Agreement to the contrary not-withstanding, in the event it shall be determined that any payment or distribution by the Company to or for the benefit of the Executive (whether paid or payable or distributed or distributable pursuant
to the terms of this Agreement or otherwise) (a "Payment") would be nondeductible by the Company for Federal income tax purposes because of Section 280G of the Code, then the aggregate present value of amounts payable or distributable to or for the
benefit of the Executive pursuant to this Agreement (such payments or distributions pursuant to this Agreement are hereinafter referred to as "Agreement Payments") shall be reduced (but not below zero) to the Reduced Amount. The "Reduced Amount" shall be
an amount expressed in present value which maximizes the aggregate present value of Agreement Payments without causing any Payment to be nondeductible by the Company because of Section 280G of the Code. For purposes of this Section 9 present value shall
be determined in accordance with Section 280G(d)(4) of the Code. |
|||||||
(b) |
All determinations required to be made under this Section 9 shall be made by BDO Seidman (the "Accounting Firm") which shall provide detailed supporting calculations both to the Company and the the Company shall elect which and how much of the
Agreement Payments shall be eliminated or reduced consistent with the requirements of this Section 9 and shall notify the Executive promptly of such election. Within five business days thereafter, the Company shall pay to or distribute to or for the
benefit of the Executive such amounts as are then due to the Executive under this Agreement. |
|||||||
(c) |
As a result of the uncertainty in the application of Section 280G of the Code at the time of the initial determination by the Accounting Firm hereunder, it is possible that Agreement Payments will have been made by the Company which should not have
been made ("Overpayment") or that additional Agreement Payments which will have not been made by the Company could have been made ("Underpayment"), in each case, consistent with the calculations required to be made hereunder. In the event that the
Accounting Firm determines that an Overpayment has been made, any such Overpayment shall be treated for all purposes as a loan to the Executive which the Executive shall repay to the Company together with interest at the applicable Federal rate provided
for in Section 7872(f)(2) of the Code; provided, however, that no amount shall be payable by the Executive to the Company (or if paid by the Executive to the Company shall be returned to the Executive) if and to the extent such payment would not reduce
the amount which is subject to taxation under Section 4999 of the Code. In the event that the Accounting Firm determines that an Underpayment has occurred, any such Underpayment shall be promptly paid by the Company to or for the benefit of the Executive
together with interest at the applicable Federal rate provided for in Section 7872(f)(2) of the Code. |
|||||||
10. |
Confidential Information. The Executive shall hold in a fiduciary capacity for the benefit of the Company all secret or confidential information, knowledge or data relating to the Company or any of its affiliated companies, and their
respective businesses, which shall have been obtained by the Executive during the Executive's employment by the Company or any of its affiliated companies and which shall not be or become public knowledge (other than by acts by the Executive or
representatives of the Executive in violation of this Agreement), After termination of the Executive's employment with the Company, the Executive shall not, without prior written consent of the Company or as may otherwise be required by law or legal
process, communicate or divulge any such information, knowledge or data to anyone other than the Company and those designated by it. In no event shall an asserted violation of the provisions of this Section 10 constitute a basis for deferring or
withholding any amounts otherwise payable to the Executive under this Agreement. |
|||||||
11. |
Successors. |
|||||||
(a) |
This Agreement is personal to the Executive and without the prior written consent of the Company shall not be assigned by the Executive otherwise than by will or the laws of descent and distribution. This Agreement shall inure to the benefit of and be enforceable by the Executive's legal representative. |
|||||||
(b) |
This Agreement shall inure to the benefit of and be binding upon the Company and its successors and assigns. |
|||||||
(c) |
The Company will require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) to al or substantially all of the business and/or assets of the Company to assume expressly and agree to perform this Agreement in the
same manner and to the same extent that the Company would be required to perform it if no such succession had taken place. As used in this Agreement, "Company" shall mean the Company as herein before defined and any successor to its business and/or assets
as aforesaid which assumes and agrees to perform this Agreement by operation of law, or otherwise. |
|||||||
12. |
Miscellaneous. |
|||||||
(a) |
This Agreement shall be governed by and construed in accordance with the laws of the State of New York, without reference to principles of conflict of laws. The captions of this Agreement are not part of the provisions hereof and shall have no force
or effect. This Agreement may not be amended or modified otherwise than by a written agreement executed by the parties hereto or their respective successors and legal representatives. |
|||||||
(b) |
All notices and other communications hereunder shall be in writing and shall be given by hand delivery to the other party or by registered or certified mail, return receipt requested, postage prepaid, addressed as follows: |
|||||||
If to the Executive: |
||||||||
Charles E. Triano |
||||||||
If to the Company: |
||||||||
Forest Laboratories, Inc. |
||||||||
or to such other address as either party shall have furnished to the other in writing in accordance herewith. Notice and communications shall be effective when actually received by addressee. |
||||||||
(c) |
The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provision of this Agreement. |
|||||||
i. |
The Company may withhold from any amounts payable under this Agreement such Federal, state, local or foreign taxes as shall be required to be withheld pursuant to any applicable law or regulation. |
|||||||
ii. |
The Executive's or the Company's failure to insist upon strict compliance with any provision of this Agreement or the failure to assert any right the Executive or the Company may have hereunder, including, without limitation, the right of the
Executive to terminate employment for Good Reason pursuant to Section 5(c)(i)(v) of this Agreement, shall not be deemed to be a waiver of such provision or right or any other provision or right of this Agreement. |
|||||||
iii. |
The Executive and the Company acknowledge that, except as |
|||||||
may otherwise be provided under any written agreement between the Executive and the Company, the employment of the Executive by the Company is "at will" and, subject to Section i(a) hereof, prior to the Effective Date, the Executive's employment and/or this Agreement may be terminated by either the Executive or the Company at any time prior to the Effective Date, in which case the Executive shall have no further rights under this Agreement. From and after the Effective Date this Agreement shall supersede any other agreement between the parties with respect to the subject matter hereof. |
||||||||
|
||||||||
IN WITNESS WHEREOF, the Executive has hereunto set the Executive's hand and, pursuant to the authorization from its Board of Directors, the Company has caused these presents to be executed in its name on its behalf, all as of the day and year first above written. |
||||||||
|
||||||||
For the Employee: |
||||||||
/s/ Charles E. Triano |
||||||||
Charles E. Triano |
||||||||
FOREST LABORATORIES, INC. |
||||||||
By: |
||||||||
/s/ Kenneth E. Goodman |
||||||||
Kenneth E. Goodman |
||||||||
President and Chief Operating Officer |
EXHIBIT 13
QUARTERLY STOCK MARKET PRICES
|
High |
Low |
April-June 1999 |
28.625 |
20.625 |
July-September 1999 |
27 |
20.875 |
October-December 1999 |
30.875 |
21.0625 |
January-March 2000 |
43.625 |
28.6875 |
April-June 2000 |
51.625 |
37.375 |
July-September 2000 |
60.3438 |
40 |
October-December 2000 |
70.6563 |
53.9375 |
January-March 2001 |
72.12 |
55.6563 |
As of June 5, 2001 there were 2,105 stockholders of record of the Company's common stock.
SELECTED FINANCIAL DATA
March 31, (In thousands) |
2001 |
|
2000 |
|
1999 |
|
1998 |
|
1997 |
|
Financial Position: |
|
|
|
|
|
|
|
|
|
|
Current Assets |
$ 884,149 |
|
$ 676,472 |
|
$527,061 |
|
$396,774 |
|
$377,533 |
|
Current Liabilities |
223,618 |
|
242,329 |
|
154,660 |
|
155,016 |
|
91,447 |
|
Net Current Assets |
660,531 |
|
434,143 |
|
372,401 |
|
241,758 |
|
286,086 |
|
Total Assets |
1,446,930 |
|
1,128,881 |
|
899,797 |
|
769,450 |
|
718,184 |
|
Total Shareholders' Equity |
1,222,114 |
|
884,690 |
|
743,512 |
|
614,161 |
|
626,399 |
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended March 31, (In thousands, |
|
|
|
|
|
|
|
|
|
|
except per share data) |
2001 |
|
2000 |
|
1999 |
|
1998 |
|
1997 |
|
Summary of Operations: |
|
|
|
|
|
|
|
|
|
|
Net Sales |
$1,174,527 |
|
$872,822 |
|
$546,266 |
|
$427,086 |
|
$280,745 |
|
Other Revenue |
30,647 |
|
26,479 |
|
77,722 |
|
47,618 |
|
28,316 |
|
Costs and Expenses |
906,447 |
|
741,854 |
|
513,185 |
|
419,932 |
|
348,060 |
|
Income (Loss) Before Income Taxes (Benefit) |
298,727 |
|
157,447 |
|
110,803 |
|
54,772 |
|
( 38,999 |
) |
Income Taxes (Benefit) |
83,631 |
|
44,759 |
|
33,630 |
|
18,075 |
|
( 15,458 |
) |
Net Income (Loss) |
215,096 |
|
112,688 |
|
77,173 |
|
36,697 |
|
( 23,541 |
) |
Net Income (Loss) Per Share: |
|
|
|
|
|
|
|
|
|
|
Basic |
$1.23 |
|
$0.67 |
|
$0.47 |
|
$0.23 |
|
($0.14 |
) |
Diluted |
$1.18 |
|
$0.64 |
|
$0.45 |
|
$0.22 |
|
($0.14 |
) |
Weighted Average Number of |
|
|
|
|
|
|
|
|
|
|
Common and Common |
|
|
|
|
|
|
|
|
|
|
Equivalent Shares |
|
|
|
|
|
|
|
|
|
|
Outstanding (Note A): |
|
|
|
|
|
|
|
|
|
|
Basic |
174,528 |
|
167,566 |
|
162,890 |
|
161,812 |
|
172,036 |
|
Diluted |
182,984 |
|
175,890 |
|
171,912 |
|
166,850 |
|
172,036 |
|
|
|
|
|
|
|
|
|
|
|
|
No dividends were paid on common shares in any period.
A. Basic net income (loss) per share was computed by dividing net income (loss) by the weighted average number of common shares outstanding during each year. Diluted net income (loss) per share includes the potential dilution that could occur if options
and warrants outstanding were included in the weighted average number of common shares outstanding for the period.
FOREST LABORATORIES, INC. AND SUBSIDIARIES
CONSOLIDATED FINANCIAL STATEMENTS
YEARS ENDED MARCH 31, 2001, 2000 AND 1999
- 1 -
REPORT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS
Board of Directors and Shareholders
Forest Laboratories, Inc.
New York, New York
We have audited the accompanying consolidated balance sheets of Forest Laboratories, Inc. and Subsidiaries as of March 31, 2001 and 2000, and the related consolidated statements of income, comprehensive income, shareholders' equity and cash flows for each of the three years in the period ended March 31, 2001. These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these financial statements based on our audits.
We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of Forest Laboratories, Inc. and Subsidiaries as of March 31, 2001 and 2000, and the results of their operations and their cash flows for each of the three years in the period ended March 31, 2001 in conformity with accounting principles generally accepted in the United States of America.
BDO SEIDMAN, LLP
New York, New York
April 20, 2001
- 2 -
FOREST LABORATORIES, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(In thousands)
|
MARCH 31, |
||
|
2001 |
|
2000 |
Assets |
|
|
|
|
|
|
|
Current assets: |
|
|
|
Cash (including cash equivalent investments of |
$ 379,549 |
|
$ 302,600 |
Marketable securities |
25,724 |
|
35,019 |
Accounts receivable, less allowance for doubtful |
115,591 |
|
91,809 |
Inventories, net |
263,957 |
|
177,798 |
Deferred income taxes |
64,357 |
|
49,568 |
Refundable income taxes |
25,024 |
|
11,321 |
Other current assets |
9,947 |
|
8,357 |
Total current assets |
884,149 |
|
676,472 |
|
|
|
|
Marketable securities |
100,451 |
|
17,619 |
|
|
|
|
Property, plant and equipment: |
|
|
|
Land and buildings |
109,547 |
|
93,362 |
Machinery and equipment |
71,671 |
|
59,607 |
Vehicles and other |
11,235 |
|
9,567 |
|
192,453 |
|
162,536 |
Less accumulated depreciation |
55,544 |
|
45,520 |
|
136,909 |
|
117,016 |
Other assets: |
|
|
|
Excess of cost of investment in subsidiaries over |
14,965 |
|
15,591 |
License agreements, product rights and other |
274,587 |
|
262,676 |
Deferred income taxes |
11,210 |
|
19,435 |
Other |
24,659 |
|
20,072 |
|
325,421 |
|
317,774 |
|
|
|
|
|
$1,446,930 |
|
$1,128,881 |
|
======== |
|
======== |
See accompanying notes to consolidated financial statements.
- 3 -
FOREST LABORATORIES, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(In thousands, except for par values)
|
MARCH 31, |
||
|
2001 |
2000 |
|
Liabilities and Shareholders' Equity |
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
Accounts payable |
$ 41,921 |
$ 71,976 |
|
Accrued expenses |
139,138 |
125,762 |
|
Income taxes payable |
42,559 |
44,591 |
|
Total current liabilities |
223,618 |
242,329 |
|
|
|
|
|
Deferred income taxes |
1,198 |
1,862 |
|
|
|
|
|
Commitments and contingencies |
|
|
|
|
|
|
|
Shareholders' equity: |
|
|
|
Series A junior participating preferred stock, |
|
|
|
Common stock $.10 par; shares authorized |
21,205 |
20,473 |
|
Capital in excess of par |
546,649 |
417,081 |
|
Retained earnings |
960,118 |
745,022 |
|
Accumulated other comprehensive loss |
( 19,573) |
( 14,312) |
|
|
1,508,399 |
1,168,264 |
|
Less common stock in treasury, at cost |
286,285 |
283,574 |
|
|
1,222,114 |
884,690 |
|
|
|||
|
$1,446,930 |
$1,128,881 |
|
|
======== |
======== |
See accompanying notes to consolidated financial statements.
- 4 -
FOREST LABORATORIES, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
(In thousands, except per share data)
|
YEARS ENDED MARCH 31, |
||||
|
2001 |
|
2000 |
|
1999 |
|
|
|
|
|
|
Net sales |
$1,174,527 |
|
$872,822 |
|
$546,266 |
Other income |
30,647 |
|
26,479 |
|
77,722 |
|
1,205,174 |
|
899,301 |
|
623,988 |
|
|
|
|
|
|
Costs and expenses: |
|
|
|
|
|
Cost of sales |
284,079 |
|
215,651 |
|
136,477 |
Selling, general and administrative |
516,662 |
|
455,911 |
|
325,067 |
Research and development |
105,706 |
|
70,292 |
|
51,641 |
|
906,447 |
|
741,854 |
|
513,185 |
|
|
|
|
|
|
Income before income tax expense |
298,727 |
|
157,447 |
|
110,803 |
|
|
|
|
|
|
Income tax expense |
83,631 |
|
44,759 |
|
33,630 |
|
|
|
|
|
|
Net income |
$ 215,096 |
|
$112,688 |
|
$ 77,173 |
|
======== |
|
======= |
|
======= |
Earnings per common and common |
|
|
|
|
|
equivalent share: |
|
|
|
|
|
|
|
|
|
|
|
Basic |
$1.23 |
|
$0.67 |
|
$0.47 |
|
==== |
|
==== |
|
==== |
Diluted |
$1.18 |
|
$0.64 |
|
$0.45 |
|
==== |
|
==== |
|
==== |
Weighted average number of common |
|
|
|
|
|
and common equivalent shares outstanding: |
|
|
|
|
|
|
|
|
|
|
|
Basic |
174,528 |
|
167,566 |
|
162,890 |
|
====== |
|
====== |
|
====== |
Diluted |
182,984 |
|
175,890 |
|
171,912 |
|
====== |
|
====== |
|
====== |
See accompanying notes to consolidated financial statements.
- 5 -
FOREST LABORATORIES, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(In thousands)
|
YEARS ENDED MARCH 31, |
||||
|
2001 |
|
2000 |
|
1999 |
|
|
|
|
|
|
Net income |
$215,096 |
|
$112,688 |
|
$77,173 |
|
|
|
|
|
|
Other comprehensive loss, net of tax: |
|
|
|
|
|
Foreign currency translation losses |
( 6,620) |
|
( 6,770) |
|
( 2,682) |
Unrealized gains (losses) on securities: |
|
|
|
|
|
Unrealized holding gain (loss) arising |
|
|
|
|
|
during the period (available-for-sale) |
1,359 |
|
( 367) |
|
37 |
Other comprehensive loss |
( 5,261) |
|
( 7,137) |
|
( 2,645) |
|
|
|
|
|
|
Comprehensive income |
$209,835 |
|
$105,551 |
|
$74,528 |
|
======= |
|
======= |
|
====== |
See accompanying notes to consolidated financial statements.
- 6 -
FOREST LABORATORIES, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY
YEARS ENDED MARCH 31, 2001, 2000 AND 1999
(In thousands)
|
Common stock |
|
Capital in |
Retained |
|
Accumulated other comprehensive |
Treasury stock |
|||
|
Shares |
Amount |
|
par |
earnings |
|
loss |
Shares |
|
Amount |
|
|
|
|
|
|
|
|
|
|
|
Balance, April 1, 1998 |
196,108 |
$19,611 |
|
$324,976 |
$555,161 |
|
($ 4,530) |
35,302 |
|
$281,056 |
|
|
|
|
|
|
|
|
|
|
|
Shares issued upon exercise of stock |
|
|
|
|
|
|
|
|
|
|
options and warrants |
5,600 |
560 |
|
33,447 |
|
|
|
|
|
|
Treasury stock acquired from employees |
|
|
|
|
|
|
|
|
|
|
upon exercise of stock options |
|
|
|
|
|
|
|
64 |
|
1,426 |
Tax benefit related to stock options |
|
|
|
|
|
|
|
|
|
|
exercised by employees |
|
|
|
22,242 |
|
|
|
|
|
|
Other comprehensive loss |
|
|
|
|
|
|
( 2,645) |
|
|
|
Net income |
|
|
|
|
77,173 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance, March 31, 1999 |
201,708 |
20,171 |
|
380,665 |
632,334 |
|
( 7,175) |
35,366 |
|
282,482 |
|
|
|
|
|
|
|
|
|
|
|
Shares issued upon exercise of stock |
|
|
|
|
|
|
|
|
|
|
options and warrants |
3,020 |
302 |
|
20,085 |
|
|
|
|
|
|
Treasury stock acquired from employees |
|
|
|
|
|
|
|
|
|
|
upon exercise of stock options |
|
|
|
|
|
|
|
40 |
|
1,092 |
Tax benefit related to stock options |
|
|
|
|
|
|
|
|
|
|
exercised by employees |
|
|
|
16,331 |
|
|
|
|
|
|
Other comprehensive loss |
|
|
|
|
|
|
( 7,137) |
|
|
|
Net income |
|
|
|
|
112,688 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance, March 31, 2000 |
204,728 |
20,473 |
|
417,081 |
745,022 |
|
( 14,312) |
35,406 |
|
283,574 |
|
|
|
|
|
|
|
|
|
|
|
Shares issued upon exercise of stock |
|
|
|
|
|
|
|
|
|
|
options and warrants |
7,324 |
732 |
|
51,879 |
|
|
|
|
|
|
Treasury stock acquired from employees |
|
|
|
|
|
|
|
|
|
|
upon exercise of stock options |
|
|
|
|
|
|
|
45 |
|
2,711 |
Tax benefit related to stock options |
|
|
|
|
|
|
|
|
|
|
exercised by employees |
|
|
|
77,689 |
|
|
|
|
|
|
Other comprehensive loss |
|
|
|
|
|
|
( 5,261) |
|
|
|
Net income |
|
|
|
|
215,096 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance, March 31, 2001 |
212,052 |
$21,205 |
|
$546,649 |
$960,118 |
|
($19,573) |
35,451 |
|
$286,285 |
|
====== |
===== |
|
====== |
====== |
|
===== |
===== |
|
====== |
See accompanying notes to consolidated financial statements.
- 7 -
FOREST LABORATORIES, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
|
YEARS ENDED MARCH 31, |
||
|
2001 |
2000 |
1999 |
Cash flows from operating activities: |
|
|
|
Net income |
$215,096 |
$112,688 |
$ 77,173 |
Adjustments to reconcile net income to |
|
|
|
net cash provided by operating activities: |
|
|
|
Depreciation |
10,623 |
8,231 |
7,309 |
Amortization |
32,663 |
32,413 |
13,955 |
Deferred income tax expense (benefit) |
( 9,512) |
( 8,837) |
4,834 |
Foreign currency translation gain |
( 55) |
( 1,202) |
( 1,560) |
Tax benefit realized from the exercise |
|
|
|
of stock options by employees |
79,973 |
23,681 |
16,796 |
Net change in operating assets and liabilities: |
|
|
|
Decrease (increase) in: |
|
|
|
Accounts receivable, net |
( 23,782) |
( 9,815) |
( 15,403) |
Inventories, net |
( 86,159) |
( 45,123) |
( 49,957) |
Refundable income taxes |
( 13,703) |
1,090 |
( 2,979) |
Other current assets |
( 1,590) |
( 2,183) |
2,332 |
Increase (decrease) in: |
|
|
|
Accounts payable |
( 30,055) |
5,303 |
36,264 |
Accrued expenses |
13,376 |
62,948 |
( 33,311) |
Income taxes payable |
( 2,032) |
19,418 |
( 3,309) |
Increase in other assets |
( 4,587) |
( 2,387) |
( 5,783) |
|
|
|
|
Net cash provided by operating activities |
180,256 |
196,225 |
46,361 |
|
|
|
|
Cash flows from investing activities: |
|
|
|
Purchase of property, plant and equipment, net |
( 30,872) |
( 35,322) |
( 17,166) |
Purchase of marketable securities: |
|
|
|
Available-for-sale |
( 113,672) |
( 15,997) |
( 56,538) |
Redemption of marketable securities: |
|
|
|
Available-for-sale |
40,136 |
41,354 |
58,490 |
Purchase of license agreements, product |
|
|
|
rights and other intangible assets |
( 44,030) |
( 100,231) |
( 12,000) |
|
|
|
|
Net cash used in investing activities |
( 148,438) |
( 110,196) |
( 27,214) |
|
|
|
|
Cash flows from financing activities: |
|
|
|
Net proceeds from common stock options |
|
|
|
exercised by employees under stock option plans |
49,900 |
19,296 |
32,581 |
|
|
|
|
Effect of exchange rate changes on cash |
( 4,769) |
( 3,693) |
( 413) |
|
|
|
|
Increase in cash and cash equivalents |
76,949 |
101,632 |
51,315 |
Cash and cash equivalents, beginning of year |
302,600 |
200,968 |
149,653 |
Cash and cash equivalents, end of year |
$379,549 |
$302,600 |
$200,968 |
|
======= |
======= |
======= |
See accompanying notes to consolidated financial statements.
- 8 -
FOREST LABORATORIES, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
|
YEARS ENDED MARCH 31, |
||
|
2001 |
2000 |
1999 |
Supplemental disclosures of cash flow |
|
|
|
information: |
|
|
|
Cash paid during the year for: |
|
|
|
Income taxes |
$29,212 |
$9,910 |
$18,340 |
|
====== |
===== |
====== |
See accompanying notes to consolidated financial statements.
- 9 -
FOREST LABORATORIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. Summary of significant accounting policies:
Basis of consolidation: The consolidated financial statements include the accounts of Forest Laboratories, Inc. (the "Company") and its subsidiaries, all of which are wholly owned. All significant intercompany accounts and transactions have been eliminated.
Foreign currency translation: An Irish subsidiary of the Company reports its financial position and results of operations in the reporting currency of the Company. The financial position and results of operations of the Company's other foreign subsidiaries, which are in aggregate immaterial, are determined using the respective local currency.
Cash equivalents: Cash equivalents consist of short-term, highly liquid investments (primarily municipal bonds with interest rates that are re-set monthly) which are readily convertible into cash at par value (cost).
Inventories: Inventories are stated at the lower of cost or market, with cost determined on the first-in, first-out basis.
Marketable securities: Marketable securities are stated at fair value or historical cost in accordance with Statement of Financial Accounting Standards No. 115, "Accounting for Certain Investments in Debt and Equity Securities," and consist of investments in municipal bonds maturing through 2003 and a bond of the Commonwealth of Puerto Rico maturing in 2002.
Property, plant and equipment and depreciation: Property, plant and equipment are stated at cost. Depreciation is provided over the estimated useful lives of the assets primarily by the straight-line method.
Intangible assets: The excess of cost of investment over the fair value of net assets of subsidiaries at the time of acquisition is being amortized using the straight-line method over 25 to 40 years. The costs of obtaining license agreements, product rights and other intangible assets are being amortized using the straight-line method over the estimated lives of the assets, 4 to 40 years.
Revenue recognition: Sales are recorded in the period the merchandise is shipped. Provisions for estimated sales allowances, returns, rebates and other pricing adjustments are accrued at the time revenues are recognized as a direct reduction of such revenue. Certain provisions are reflected either as a direct reduction to accounts receivable or, to the extent that they are due to entities other than customers, as accrued expense. Adjustments to estimates, which have not been material, are recorded when customer credits are issued or payments made to third parties.
Shipping and handling costs: Presently, the Company does not charge its customers for any freight costs. The amounts of such costs are included in selling, general and administrative expenses and are not material.
Research and development: Expenditures for research and development, including licensing fees of early-stage development products, are charged to expense as incurred.
Savings and profit sharing plan: Substantially all non-bargaining unit employees of the Company's domestic subsidiaries may participate in the savings and profit sharing plan after becoming eligible (as defined). Profit sharing contributions are primarily at the discretion of the Company. The savings plan contributions include a matching contribution made by the Company. Savings and profit sharing contributions amounted to approximately $8,200,000, $6,800,000 and $6,300,000 for fiscal years 2001, 2000 and 1999, respectively.
- 10 -
FOREST LABORATORIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
1. Summary of significant accounting policies: (Continued)
Earnings per share: Basic earnings per share includes no dilution and is computed by dividing income available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflect, in periods in which they have a dilutive effect, the effect of common shares issuable upon exercise of stock options and warrants. The two-for-one stock split effected as a 100% stock dividend in December 2000 has been reflected retroactively for all outstanding common stock and stock options.
Accumulated other comprehensive loss: Other comprehensive loss refers to revenues, expenses, gains and losses that under generally accepted accounting principles are excluded from net income as these amounts are recorded directly as an adjustment to shareholders' equity. Accumulated other comprehensive loss is comprised of the cumulative effects of foreign currency translation and unrealized gains (losses) on securities which amounted to approximately $20,302,000 and $13,682,000, and $729,000 and ($630,000) at March 31, 2001 and March 31, 2000, respectively.
Income taxes: The Company accounts for income taxes using the liability method. Under the liability method, deferred income taxes are provided on the differences in bases of assets and liabilities between financial reporting and tax returns using enacted tax rates.
Use of estimates: The preparation of financial statements in conformity with generally accepted accounting principles requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company reviews all significant estimates affecting the financial statements on a recurring basis and records the effect of any adjustments when necessary.
Long-lived assets: Long-lived assets, such as goodwill, intangible assets, property and equipment and certain sundry assets, are evaluated for impairment when events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable through the estimated undiscounted future cash flows from the use of these assets. When any such impairment exists, the related assets will be written down to fair value.
Stock-based compensation: The Company accounts for its stock option awards to employees under the intrinsic value based method of accounting prescribed by Accounting Principles Board Opinion No. 25, "Accounting for Stock Issued to Employees." Under the intrinsic value based method, compensation cost is the excess, if any, of the quoted market price of the stock at grant date or other measurement date over the amount an employee must pay to acquire the stock. The Company makes pro forma disclosures of net income and earnings per share as if the fair value based method of accounting had been applied as required by Statement of Financial Accounting Standards No. 123 ("SFAS 123"), "Accounting for Stock-Based Compensation."
Fair value of financial instruments: The carrying amounts of cash, accounts receivable, accounts payable, accrued expenses and income taxes payable are reasonable estimates of their fair value because of the short maturity of these items.
- 11 -
FOREST LABORATORIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
1. Summary of significant accounting policies: (Continued)
Reclassifications: Certain amounts as previously reported have been reclassified to conform to current year classifications.
Recent accounting standards: In December 1999, the Securities and Exchange Commission ("SEC") issued Staff Accounting Bulletin No. 101 ("SAB No. 101"), "Revenue Recognition in Financial Statements." SAB No. 101 summarizes certain of the SEC's views in applying generally accepted accounting principles to revenue recognition in the financial statements. In October 2000, the SEC issued additional written guidance to further supplement SAB No. 101. The adoption of this bulletin had no effect on the consolidated financial statements.
In June 1998, the Financial Accounting Standards Board issued Statement of Financial Accounting Standards No. 133 ("SFAS 133"), "Accounting for Derivative Instruments and Hedging Activities." SFAS 133 is effective for the Company on April 1, 2001. SFAS 133 requires that all derivative instruments be recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether a derivative is designated as part of the hedge transaction and the type of hedge transaction. The ineffective portion of all hedges will be recognized in earnings. Presently, the Company does not utilize any derivative instruments or hedging activities.
2. Earnings per share:
A reconciliation of shares used in calculating basic and diluted earnings per share follows:
(In thousands) |
2001 |
2000 |
1999 |
Basic |
174,528 |
167,566 |
162,890 |
Effect of assumed conversion |
|
|
|
of employee stock options |
|
|
|
and warrants |
8,456 |
8,324 |
9,022 |
|
|
|
|
Diluted |
182,984 |
175,890 |
171,912 |
|
====== |
====== |
====== |
Options and warrants to purchase approximately 2,407,400, 63,000 and 893,600 shares of common stock at exercise prices ranging from $24.18 to $66.91 per share were outstanding during a portion of fiscal 2001, 2000 and 1999, respectively, but were not included in the computation of diluted earnings per share because they were anti-dilutive. These options and warrants expire through 2010.
3. Acquisitions:
Product licenses and rights: (i) During the current fiscal year, the Company entered into several licensing agreements with various companies as follows: Merz + Co. for memantine for the treatment of Alzheimer's Disease and neuropathic pain, Rotta Research Laboratorium S.p.A. for dexloxiglumide for the treatment of irritable bowel syndrome and Recordati S.p.A. Chemical and Pharmaceutical Company for lercanidipine, for the treatment of hypertension. The costs incurred upon the signing of these agreements were included in license agreements, product rights and other intangible assets and will be amortized, using the straight-line method, over the estimated lives of the products upon launch.
- 12 -
FOREST LABORATORIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
3. Acquisitions: (Continued)
(ii) Also during the current year, the Company entered into agreements with Allelix Corp. for ALX-0646, which is being investigated for its role in the treatment of migraine headaches and with Merz + Co. for neramexane, which is being investigated for use in several illnesses of the central nervous system. Any costs incurred in obtaining these licenses were charged to research and development expense, as they are in early-stage development.
(iii) On March 27, 2000, the Company entered into a licensing agreement with Merckle GmbH for ML3000, which is being investigated for its role in the treatment of osteoarthritis. The cost incurred upon signing the contract was included in research and development expenses in fiscal 2000, as the product had not yet entered final phase testing.
4. Business operations:
The Company and its subsidiaries, which are located in the United States, Ireland and the United Kingdom, manufacture and market ethical and other pharmaceutical products. The Company operates in only one segment. Sales are made primarily in the United States and European markets. The net sales and long-lived assets for the years ended March 31, 2001, 2000 and 1999, are from the Company's or one of its subsidiaries' country of origin, as follows:
|
|
|
|
|
|
||||||
(In thousands) |
2001 |
|
2000 |
|
1999 |
||||||
|
|
|
Long-lived |
|
|
|
Long-lived |
|
|
|
Long-lived |
|
Net sales |
|
assets |
|
Net sales |
|
assets |
|
Net sales |
|
assets |
United States |
$1,138,156 |
|
$365,619 |
|
$836,191 |
|
$365,206 |
|
$509,222 |
|
$276,113 |
Ireland |
6,003 |
|
82,090 |
|
5,475 |
|
46,577 |
|
4,076 |
|
39,997 |
United Kingdom |
30,368 |
|
4,253 |
|
31,156 |
|
4,045 |
|
32,968 |
|
4,191 |
|
$1,174,527 |
|
$451,962 |
|
$872,822 |
|
$415,828 |
|
$546,266 |
|
$320,301 |
|
======== |
|
======= |
|
======= |
|
======= |
|
======= |
|
======= |
For the year ended March 31, 2001, McKesson Drug Company, Cardinal Distributors, Inc., Amerisource Corporation and Bergen Brunswig Corporation accounted for 22%, 17%, 12% and 11%, respectively, of the Company's net sales. For the years ended March 31, 2000 and 1999, McKesson Drug Company, Cardinal Distributors, Inc., Amerisource Corporation and Bergen Brunswig Corporation accounted for 19%, 13%, 12% and 14%, and 17%, 14%, 8% and 12%, respectively, of the Company's net sales.
Sales of Celexa™, a selective serotonin reuptake inhibitor ("SSRI") for the treatment of depression, launched in September 1998, accounted for 61%, 49% and 17% of the Company's net sales for the years ended March 31, 2001, 2000 and 1999, respectively.
5. Inventories:
Inventories, net of reserves for obsolescence, consist of the following:
March 31, (In thousands) |
2001 |
2000 |
Raw materials |
$135,844 |
$ 35,976 |
Work in process |
11,709 |
12,766 |
Finished goods |
116,404 |
129,056 |
|
$263,957 |
$177,798 |
|
======= |
======= |
- 13 -
FOREST LABORATORIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
6. Marketable securities:
The composition of the investment portfolio at March 31 was:
|
|
Gross |
Gross |
|
|
|
unrealized |
unrealized |
Market |
(In thousands) |
Cost |
gains |
losses |
value |
2001 |
|
|
|
|
Available-for-sale : |
|
|
|
|
State and local obligations |
$123,446 |
$729 |
|
$124,175 |
|
|
|
|
|
Held-to-maturity : |
|
|
|
|
Foreign government obligations |
2,000 |
6 |
|
2,006 |
|
$125,446 |
$735 |
|
$126,181 |
|
======= |
==== |
|
======= |
2000 |
|
|
|
|
Available-for-sale : |
|
|
|
|
State and local obligations |
$51,268 |
|
($630) |
$50,638 |
|
|
|
|
|
Held-to-maturity : |
|
|
|
|
Foreign government obligations |
2,000 |
$33 |
|
2,033 |
|
$53,268 |
$33 |
($630) |
$52,671 |
|
====== |
=== |
==== |
====== |
The contractual maturities of debt securities at March 31, 2001, regardless of their balance sheet classification, consist of the following:
|
Amortized |
Fair |
(In thousands) |
cost |
value |
Available-for-sale : |
|
|
Less than one year |
$ 25,665 |
$ 25,724 |
One to two years |
97,781 |
98,451 |
|
123,446 |
124,175 |
Held-to-maturity |
|
|
One to two years |
2,000 |
2,006 |
|
$125,446 |
$126,181 |
|
======= |
======= |
The net unrealized holding gains from available-for-sale securities at March 31, 2001 of approximately $729,000 as well as the net unrealized holding losses from available-for-sale securities of approximately $630,000 at March 31, 2000 and approximately $263,000 at March 31, 1999 are included in Shareholders' equity: Accumulated other comprehensive loss.
7. Other assets:
License agreements, product rights and other intangible assets consist of the following:
(In thousands, except for estimated lives |
|
|
|
which are stated in years) |
Estimated |
|
|
March 31, |
lives |
2001 |
2000 |
License agreements |
10-40 |
$188,192 |
$156,662 |
Product rights |
10-15 |
51,047 |
38,547 |
Buy-out of royalty agreements (refer to Note 12) |
4-10 |
95,000 |
95,000 |
Trade names |
20-40 |
34,190 |
34,190 |
Goodwill |
25-40 |
29,412 |
29,412 |
Non-compete agreements |
10-13 |
22,987 |
22,987 |
Customer lists |
10 |
3,506 |
3,506 |
Other |
10-40 |
1,597 |
1,679 |
|
|
425,931 |
381,983 |
Less accumulated amortization |
|
( 151,344) |
( 119,307) |
|
|
$274,587 |
$262,676 |
|
|
======= |
======= |
- 14 -
FOREST LABORATORIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
8. Accrued expenses:
Accrued expenses consist of the following:
March 31, (In thousands) |
2001 |
2000 |
Employee compensation and other benefits |
$ 35,070 |
$ 21,897 |
Rebates |
60,859 |
32,532 |
Clinical research and development costs |
27,341 |
22,229 |
Royalties |
4,535 |
4,369 |
Co-promotion fee (refer to Note 12) |
|
29,771 |
Other |
11,333 |
14,964 |
|
$139,138 |
$125,762 |
|
======= |
======= |
9. Commitments:
Leases: The Company leases manufacturing, office and warehouse facilities, equipment and automobiles under operating leases expiring through 2018. Rent expense approximated $15,034,000, $9,797,000 and $8,444,000 for fiscal years ended 2001, 2000 and 1999, respectively. Aggregate minimum rentals under noncancellable leases are as follows:
Year ending March 31, (In thousands)
2002 |
$ 15,942 |
2003 |
15,345 |
2004 |
12,271 |
2005 |
9,309 |
2006 |
8,374 |
Thereafter |
58,075 |
|
$119,316 |
|
======= |
Royalty agreements: The Company has royalty agreements on certain of its licensed products. Royalties are paid based on a percentage of sales, as defined. For fiscal years ended 2001, 2000 and 1999, royalties amounted to $19,977,000, $17,039,000 and $16,240,000, respectively.
10. Shareholders' equity:
Preferred stock purchase rights: On September 30, 1994, the Company's Board of Directors declared a dividend of one preferred share purchase right (a "Right") for each outstanding share of the Company's common stock, par value $.10 per
share. Each Right will entitle the holder to buy one quarter of one-hundredth of a share of authorized Series A Junior Participating Preferred Stock, par value $1.00 per share ("Series A Preferred Stock") at an exercise price of $250 per Right, subject to
adjustment. Prior to becoming exercisable, the Rights are evidenced by the certificates representing the common stock and may not be traded apart from the common stock. The Rights become exercisable on the tenth day after public announcements that a
person or group has acquired, or obtained the right to acquire, 20% or more of the Company's outstanding common stock, or an announcement of a tender offer that would result in a beneficial ownership by a person or group of 20% or more of the Company's
common stock.
- 15 -
FOREST LABORATORIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
10. Shareholders equity: (Continued)
If, after the Rights become exercisable, the Company is a party to certain merger or business combination transactions, or transfers 50% or more of its assets or earning power, or if an acquirer engages in certain self-dealing transactions, each Right (except for those held by the acquirer) will entitle its holder to buy a number of shares of the Company's Series A Preferred Stock or, in certain circumstances, a number of shares of the acquiring company's common stock, in either case having a value equal to two-and-one-half times the exercise price of the Right. The Rights may be redeemed by the Company at any time up to ten days after a person or group acquires 20% or more of the Company's common stock at a redemption price of $.001 per Right. The Rights will expire on September 30, 2004.
The Company has reserved 900,000 shares of Series A Preferred Stock for the exercise of the Rights.
Stock options: The Company has various Employee Stock Option Plans whereby options to purchase an aggregate of 31,600,000 shares of common stock have been or remain to be issued to employees of the Company and its subsidiaries at prices not less than the fair market value of the common stock at the date of grant. Both incentive and non-qualified options may be issued under the plans. The options are exercisable up to the tenth anniversary of the date of issuance.
SFAS No. 123 requires the Company to provide pro forma information regarding net income and earnings per share as if compensation cost for the Company's stock option plans had been determined in accordance with the fair value of each stock option at the grant date by using the Black-Scholes option-pricing model with the following weighted average assumptions used for grants: dividend yield of zero for all three years; expected volatility of 43.59% in fiscal 2001, 38.25% in fiscal 2000 and 39.26% in fiscal 1999; risk-free interest rates of between 4.9% and 6.5% in fiscal 2001, 6% in fiscal 2000 and 6% in fiscal 1999; and expected lives of 5 to 10 years for all three years.
Under the accounting provisions of SFAS No. 123, the Company's net income and earnings per share would have been reduced to the pro forma amounts indicated below:
(In thousands, except per share data) |
2001 |
2000 |
1999 |
|
|
|
|
Net income: |
|
|
|
As reported |
$215,096 |
$112,688 |
$77,173 |
Pro forma |
169,815 |
89,836 |
64,083 |
|
|
|
|
Net income per common share: |
|
|
|
Basic: |
|
|
|
As reported |
$1.23 |
$0.67 |
$0.47 |
Pro forma |
0.97 |
0.54 |
0.40 |
|
|
|
|
Diluted: |
|
|
|
As reported |
$1.18 |
$0.64 |
$0.45 |
Pro forma |
0.93 |
0.51 |
0.38 |
- 16 -
FOREST LABORATORIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
10. Shareholders' equity: (Continued)
The following table summarizes information about stock options outstanding at March 31, 2001:
|
|
Options outstanding |
Options exercisable |
|||
|
|
Number |
Weighted average |
|
Number |
|
Range of |
|
outstanding |
remaining |
Weighted average |
exercisable |
Weighted average |
exercise prices |
|
at 3/31/01 |
contractual life |
exercise price |
at 3/31/01 |
exercise price |
|
|
|
|
|
|
|
$ 7.42 to $15.00 |
|
7,354,877 |
3.4 |
$10.26 |
4,720,817 |
$10.58 |
15.01 to 35.00 |
|
5,030,911 |
5.9 |
24.10 |
2,075,731 |
24.52 |
35.01 to 66.91 |
|
4,600,850 |
6.8 |
56.46 |
20,280 |
49.59 |
|
|
16,986,638 |
5.1 |
$26.87 |
6,816,828 |
$14.94 |
Transactions under the stock option plans and individual non-qualified options not under the plans are summarized as follows:
|
|
Weighted average |
|
Shares |
exercise price |
Shares under option at March 31, 1998 |
|
|
(at $2.48 to $15.38 per share) |
22,256,828 |
$ 8.33 |
Granted (at $16.85 to $24.18 per share) |
2,403,370 |
21.12 |
Exercised (at $2.48 to $15.38 per share) |
( 4,781,616) |
7.29 |
Cancelled |
( 687,742) |
10.40 |
|
|
|
Shares under option at March 31, 1999 |
|
|
(at $5.42 to $24.18 per share) |
19,190,840 |
10.08 |
Granted (at $24.58 to $33.38 per share) |
3,311,700 |
26.08 |
Exercised (at $5.42 to $24.18 per share) |
( 2,662,356) |
7.82 |
Cancelled |
( 456,330) |
14.59 |
|
|
|
Shares under option at March 31, 2000 |
|
|
(at $6.06 to $33.38 per share) |
19,383,854 |
13.02 |
Granted (at $42.17 to $66.91 per share) |
4,659,750 |
56.40 |
Exercised (at $6.06 to $33.38 per share) |
( 6,840,706) |
7.63 |
Cancelled |
( 216,260) |
30.12 |
|
|
|
Shares under option at March 31, 2001 |
|
|
(at $7.42 to $66.91 per share) |
16,986,638 |
$26.87 |
|
|
|
Options exercisable at March 31: |
|
|
1999 |
10,721,766 |
$ 7.98 |
2000 |
10,443,796 |
$ 9.29 |
2001 |
6,816,828 |
$14.94 |
|
|
|
Weighted average fair value |
|
|
of options granted during: |
|
|
1999 |
$10.33 |
|
2000 |
$14.27 |
|
2001 |
$31.60 |
|
At March 31, 2001, 2000 and 1999, 7,817,532, 4,256,400 and 7,143,820 shares, respectively, were available for grant.
In connection with the acquisition of product rights in fiscal 1995, the Company issued 1,120,000 warrants, which expire on July 7, 2004, at an exercise price of $11.43 per share which was equal to the then fair market value of the Company's common stock. As of March 31, 2001, 65,728 warrants remain outstanding.
- 17 -
FOREST LABORATORIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
11. Contingencies:
The Company remains a defendant in actions filed in various federal district courts alleging certain violations of the federal anti-trust laws in the marketing of pharmaceutical products. In each case, the actions were filed against many pharmaceutical manufacturers and suppliers and allege price discrimination and conspiracy to fix prices in the sale of pharmaceutical products. The actions were brought by various pharmacies (both individually and, with respect to certain claims, as a class action) and seek injunctive relief and monetary damages. The Judicial Panel on Multi-District Litigation has ordered these actions coordinated (and, with respect to those actions brought as class actions, consolidated) in the Federal District Court for the Northern District of Illinois (Chicago) under the caption "In re Brand Name Prescription Drugs Antitrust Litigation."
On November 30, 1998, the defendants remaining in the consolidated federal class action (which proceeded to trial beginning in September 1998), including the Company, were granted a directed verdict by the trial court after the plaintiffs had concluded their case. In ruling in favor of the defendants, the trial judge held that no reasonable jury could reach a verdict in favor of the plaintiffs and stated "the evidence of conspiracy is meager, and the evidence as to individual defendants paltry or non-existent." The Court of Appeals for the Seventh Circuit subsequently affirmed the granting of the directed verdict in the federal class case in favor of the Company.
Following the Seventh Circuit's affirmance of the directed verdict in favor of the Company, the Company has secured the voluntary dismissal of the conspiracy allegations contained in all of the federal cases brought by individual plaintiffs who elected to "opt-out" of the federal class action, which cases were included in the coordinated proceedings, as well as the dismissal of similar conspiracy and price discrimination claims pending in various state courts. The Company, together with other manufacturers, remains a defendant in many of the federal opt-out cases included in the coordinated proceedings to the extent of claims alleging price discrimination in violation of the Robinson-Patman Act. While no discovery or other significant proceedings have been taken to date in respect of such claims, there can be no assurance that the Company will not be required to actively defend such claims or to pay substantial amounts to dispose of such claims.
The Company is a defendant in an action pending in Federal District Court for the Northern District of Illinois entitled G.D. Searle & Co. v. Forest Laboratories, Inc. Plaintiff G.D. Searle asserts claims for federal and common law trademark infringement in respect to rights Searle alleges as to the name "Celebra" and arising from the marketing of Celexa. The action seeks injunctive relief and unspecified monetary damages. Discovery has been substantially completed although no date for trial has yet been set. The Company believes this action is without merit.
The Company is not subject to any other pending legal proceedings, other than ordinary routine claims incidental to its business.
- 18 -
FOREST LABORATORIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
12. Development and marketing agreements:
On March 27, 1998 the Company entered into an agreement with the Warner-Lambert Company to co-promote Celexa. Under that agreement Warner-Lambert would promote Celexa for three years and receive residual payments for an additional three years. Compensation for these services to Warner-Lambert was based on the profits (as defined) earned on Celexa's sales. As a result of the merger of Warner-Lambert with Pfizer, Inc., a marketer of a competing antidepressant product, the co-promotion agreement was terminated effective April 30, 2000. In connection with the termination, the Company paid $14,000,000 in the first quarter of fiscal 2001, which is included in selling, general and administrative expense. The termination ended Warner-Lambert's co-promotion activities with respect to Celexa and entitlement to future compensation therefor.
On June 30, 1999 the Company exercised its purchase option to terminate a royalty obligation to a private investor group on sales of Celexa for a predetermined one-time payment of $85,000,000. In fiscal 1999, the private investor group had reimbursed the Company a total of $38,387,000 for certain salesforce, marketing and research and development expenses in connection with the launch of Celexa, which was included in contract revenue. The investor group was to receive a royalty ranging from 25% to 5% on sales of Celexa beginning in November 1999 for a period of ten years. During the fiscal quarter ended September 30, 1999, the Company also agreed to buy out a limited 1% trailing royalty for $10,000,000.
13. Other income:
Other income consists of the following:
Years ended March 31, (In thousands) |
2001 |
2000 |
1999 |
Interest and dividends |
$22,067 |
$12,473 |
$ 9,898 |
Contract revenue |
6,827 |
8,976 |
51,235 |
Other income |
1,753 |
5,030 |
16,589 |
|
$30,647 |
$26,479 |
$77,722 |
|
====== |
====== |
====== |
The Company recorded $6,827,000, $8,976,000 and $12,848,000 in fiscal years 2001, 2000 and 1999, respectively, for Climara® contract revenue. The Company also recorded other income of $3,000,000 and $12,000,000 in fiscal years 2000 and 1999, respectively, from the settlement of its arbitration with Pharmacia & Upjohn, Inc. with respect to the Company's claimed option to negotiate for the rights to Detrol®.
14. Income taxes:
The Company and its mainland U.S. subsidiaries file a consolidated federal income tax return.
Income before income tax expense includes income from foreign operations of $111,891,000, $67,827,000 and $20,576,000 for the years ended March 31, 2001, 2000 and 1999, respectively.
The Company has a tax holiday in Ireland, which expires in 2010. The net impact of the tax holiday in fiscal years 2001, 2000 and 1999 was to increase net income and net income per share (diluted) by approximately $21,188,000 and $.12, $13,118,000 and $.08 and $5,092,000 and $.03, respectively.
- - 19 -
FOREST LABORATORIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
14. Income taxes: (Continued)
The provision for income taxes consists of the following:
|
|
|
|
Years ended March 31, (In thousands) |
2001 |
2000 |
1999 |
Current: |
|
|
|
U.S. federal |
($ 1,017) |
$19,566 |
$ 5,752 |
State and local |
2,670 |
4,087 |
3,959 |
Foreign |
11,517 |
6,262 |
2,289 |
|
13,170 |
29,915 |
12,000 |
Deferred: |
|
|
|
Domestic |
( 8,848) |
( 8,949) |
2,612 |
Foreign |
( 664) |
112 |
2,222 |
|
( 9,512) |
( 8,837) |
4,834 |
Charge in lieu of income taxes, |
|
|
|
relating to the tax effect of |
|
|
|
stock option tax deduction |
79,973 |
23,681 |
16,796 |
|
$83,631 |
$44,759 |
$33,630 |
|
====== |
====== |
====== |
No provision has been made for income taxes on the undistributed earnings of the Company's foreign subsidiaries of approximately $274,598,000 at March 31, 2001 as the Company intends to indefinitely reinvest such earnings.
Years ended March 31, (In thousands) |
2001 |
2000 |
1999 |
Expected federal income taxes |
$104,555 |
$55,106 |
$38,781 |
State and local income taxes, |
|
|
|
less federal income tax benefit |
3,489 |
2,511 |
3,178 |
Net benefit of tax-exempt earnings |
( 1,673) |
( 3,076) |
( 3,386) |
Tax effect of permanent differences |
|
|
|
(primarily due to lower tax rates for |
|
|
|
operations located in foreign countries) |
( 22,740) |
( 9,782) |
( 2,931) |
Other |
|
|
( 2,012) |
|
$ 83,631 |
$44,759 |
$33,630 |
|
======= |
====== |
====== |
Net deferred income taxes consist of the following:
March 31, (In thousands) |
2001 |
2000 |
Inventory valuation |
$10,129 |
$13,183 |
Receivable reserves and other allowances |
45,807 |
30,151 |
Depreciation |
( 2,730) |
( 2,661) |
Amortization |
2,143 |
2,734 |
Tax credits and other carryforwards |
264 |
264 |
Accrued liabilities |
6,084 |
5,978 |
Expenses deferred for tax purposes |
7,595 |
10,709 |
Employee stock option tax benefits |
6,269 |
4,500 |
Other |
( 1,192) |
2,283 |
|
$74,369 |
$67,141 |
|
====== |
====== |
- - 20 -
FOREST LABORATORIES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)
15. Quarterly financial data (unaudited):
(In thousands, except per share data)
|
|
|
|
Diluted |
|
|
|
|
earnings |
|
Net sales |
Gross profit |
Net income |
per share |
2001 |
|
|
|
|
First quarter |
$259,227 |
$195,286 |
$28,258 |
$0.16 |
Second quarter |
280,963 |
211,032 |
51,738 |
0.28 |
Third quarter |
310,086 |
236,231 |
65,913 |
0.36 |
Fourth quarter |
324,251 |
247,899 |
69,187 |
0.38 |
|
|
|
|
|
2000 |
|
|
|
|
First quarter |
$178,793 |
$134,060 |
$25,053 |
$0.14 |
Second quarter |
201,357 |
151,069 |
27,950 |
0.16 |
Third quarter |
234,413 |
175,742 |
31,756 |
0.18 |
Fourth quarter |
258,259 |
196,300 |
27,929 |
0.16 |
- - 21 -
FOREST LABORATORIES, INC. AND SUBSIDIARIES
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
Financial Condition and Liquidity
During fiscal 2001 net current assets increased by $226,388,000. Increases in cash, accounts receivable, inventories and accrued expenses resulted primarily from increases in sales, particularly Celexa™. Celexa (citalopram HBr) is the Company's selective serotonin reuptake inhibitor ("SSRI") for the treatment of depression. Inventory levels have increased to meet the growing demand for Celexa. During the year, the Company increased its investment in long-term marketable securities in order to receive more favorable rates of return on invested funds. The increase in license agreements, product rights and other intangible assets was due to several late-stage product license agreements entered into by Forest during the period. These agreements include dexloxiglumide for the treatment of irritable bowel syndrome, lercanidipine for the treatment of hypertension and memantine for the treatment of Alzheimer's Disease and neuropathic pain. The increases in capital in excess of par and refundable income taxes were due to the exercise of stock options by employees along with related tax benefits.
Property, plant and equipment increased as the result of expansions of the Company's facilities and the acquisition of new facilities to meet current and projected future product demand. Included was an expansion of Forest's Irish manufacturing facility and the acquisition of new facilities on Long Island, New York for research and development, sales support and warehousing and distribution. Further expansions and acquisitions are likely to meet the needs of increased production and research and development.
Management believes that current cash levels, coupled with funds to be generated by ongoing operations, will continue to provide adequate liquidity to facilitate potential acquisitions of products and capital investments.
Results of Operations
Net sales in fiscal 2001 increased $301,705,000 to $1,174,527,000, a 35% increase from fiscal 2000. Forest's leading product, Celexa, accounted for most of the increase with sales amounting to $714,359,000, an increase of $287,017,000 or 67% from last year. Since its launch, Celexa has continued to experience strong growth and, as of March 31, 2001, had captured a 14.2% share of total prescriptions in the SSRI market. TiazacÒ , which continues to experience volume growth, increased $18,665,000 in fiscal 2001 of which $27,136,000 was due to volume increases, offset by $8,471,000 of net price declines which was principally the result of increases in government sales at a discount. Sales of Infasurfâ , Forest's lung surfactant for the prevention and treatment of respiratory distress syndrome in premature infants, which was launched during the third quarter of fiscal 2000, amounted to $12,886,000, and accounted for $8,093,000 of the increase. Sales of AerobidÒ , which continues to experience competition in the inhaled steroid market, declined $2,146,000 or 3% during
- -1-
FOREST LABORATORIES, INC. AND SUBSIDIARIES
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
fiscal 2001 due to volume declines. Sales of Forest's generic products increased by $9,151,000 from fiscal 2000. The remainder of the net sales change was due principally to volume declines on the Company's older unpromoted
product lines. Net sales in fiscal 2000 increased $326,556,000 or 60% as compared to fiscal 1999. Celexa had the biggest impact on the sales increase, capturing a total prescription market share of 10.5% in the SSRI market. During fiscal 2000, sales of
Celexa were $427,342,000, an increase of $335,432,000 from fiscal 1999, the year it was launched. Infasurf, launched in October 1999, achieved sales of $4,794,000 in fiscal 2000. Tiazac increased $28,495,000 or 22% in fiscal 2000. Sales of Aerobid,
declined $28,693,000 or 31% in fiscal 2000 as compared to fiscal 1999. Sales of our other products decreased $17,403,000 or 8% from fiscal 1999 due primarily to volume declines.
The increase in other income during fiscal 2001 as compared to fiscal 2000 was due to increases in interest income as a result of more funds available for investment. Included in other income is contract revenue, which represents royalties on sales of Climaraâ , a transdermal estrogen product, which amounted to $6,827,000, $8,976,000, and $12,848,000 in fiscal years 2001, 2000 and 1999, respectively. Other income in fiscal years 2000 and 1999 includes $3,000,000 and $12,000,000, respectively, from the settlement with Pharmacia & Upjohn, Inc. with respect to the Company's claimed option to negotiate for the rights to Detrolâ . In fiscal 1999 other income also included $38,387,000 from our arrangement with a private investor group to reimburse Forest for certain expenses incurred in connection with Celexa (refer to Note 12 of the consolidated financial statements). The balance of other income for fiscal 2000 and fiscal 1999 was principally interest earned on invested funds.
Cost of sales as a percentage of sales was 24% in fiscal 2001 as compared to 25% in fiscal years 2000 and 1999. The decrease was due to an increase in overall plant utilization and to product mix as Celexa, with a lower cost of goods, comprised a larger portion of total sales.
Selling, general and administrative expenses increased $60,751,000 during fiscal 2001 due primarily to activities related to Celexa, including our newly expanded salesforce. During the second half of fiscal year 2000, we increased the salesforce by almost 70%, from 850 representatives and managers to 1,425 persons. This expansion was necessitated by the termination of the co-promotion arrangement with the Warner-Lambert Company on April 30, 2000. A termination payment of $14,000,000 was paid to Warner-Lambert during the first quarter that ended Warner-Lambert's co-promotion activities with respect to Celexa and entitlement to future compensation therefor. The increase in selling, general and administrative expenses in fiscal 2000 as compared to fiscal 1999 was principally due to marketing, promotional and selling activities related to Celexa, including co-promotion fees payable to Warner-Lambert. No co-promotion fees were earned in fiscal 1999.
-2-
FOREST LABORATORIES, INC. AND SUBSIDIARIES
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
During the third and fourth quarters of fiscal 2000, the Company incurred both the costs of the increased salesforce and the co-promotion fees to Warner-Lambert. During fiscal 1999, a portion of pre-launch and launch costs, together with certain research and development expenses related to Celexa, were reimbursed by the private investor group, as discussed above.
The increase in research and development expense during each of the years presented was due to costs associated with clinical trials conducted to obtain approval for new products and from staff increases and associated costs required to support currently marketed products and products in various stages of development. During the current year, particular emphasis was placed on clinical studies for escitalopram, Forest's single enantiomer form of Celexa, for which Phase III clinical trials have been completed and a New Drug Application ("NDA") was filed with the FDA during the fourth quarter. The Company also incurred expenses related to the licensing of early-stage development products. During the first quarter of fiscal 2001 the Company filed an NDA for flunisolide HFA for the treatment of asthma, for which we received an approvable letter from the FDA. As a result of the completion of several licensing agreements during fiscal 2001, the Company anticipates further increases in research and development expenses for next year and beyond. Other products in our pipeline for which we expect to file NDA's during the upcoming year include: lercanidipine, for the treatment of hypertension; our patented combination of oxycodone/ibuprofen for moderate to severe pain; and memantine, for the treatment of Alzheimer's Disease and neuropathic pain. Forest has several other on-going clinical trials in various stages including siramesine for anxiety, dexloxiglumide for the treatment of irritable bowel syndrome, ML3000 for osteoarthritis, and ALX-0646 for the treatment of migraine headaches.
Income tax expense as a percentage of income before taxes was 28% for the current year, unchanged from fiscal 2000, and 30% in fiscal 1999. The decrease from fiscal 1999 resulted principally from a decrease in the proportion of operating profit derived from fully taxable U.S. operations as compared to lower taxed operations. Celexa is licensed and manufactured in Ireland and a portion of its profits are subject to a favorable tax rate.
The Company expects to continue its profitability into fiscal 2002 with continued growth in its principal promoted products.
Inflation has not had a material effect on the Company's operations for the periods presented.
-3-
FOREST LABORATORIES, INC. AND SUBSIDIARIES
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
Forward Looking Statements
Except for the historical information contained herein, the Management Discussion and other portions of this annual report contain forward looking statements that involve a number of risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, the timely development and launch of new products and the risk factors listed from time to time in the Company's SEC reports, including the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2001.
Quantitative and Qualitative Disclosures About Market Risk
In the normal course of business, operations of the Company may be exposed to fluctuations in currency values and interest rates. These fluctuations can vary the costs of financing, investing and operating transactions. Because the Company had no debt and only minimal foreign currency transactions, there was no material impact on earnings of fluctuations in interest and currency exchange rates.
- -4-
EXHIBIT 23
CONSENT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS
Forest Laboratories, Inc.
New York, New York
We hereby consent to the incorporation by reference in the Registration Statements of Forest Laboratories, Inc. on Forms S-8, filed with the Securities and Exchange Commission on October 28, 1994, October 18, 1998 and October 26, 2000 and Form S-3 filed
with the Securities and Exchange Commission on November 30, 1993, respectively, of our reports dated April 20, 2001 on the consolidated financial statements and schedule of Forest Laboratories, Inc. appearing in the Annual Report on Form 10-K as of and
for the year ended March 31, 2001.
/s/ BDO Seidman, LLP
BDO Seidman, LLP
New York, New York
June 28, 2001